{"transactions":[{"id":4635258,"issuer":{"id":4936,"kind":"organization","name":"Avalo Therapeutics, Inc.","symbol":"AVTX"},"owners":[{"id":32667,"kind":"person","name":"Jain Rita","position":1,"cik":"0001707797","reported_name":"Jain Rita","relationship":{"director":true,"officer":false,"ten_percent_owner":false,"other":false}}],"security":"Stock Option (Right to Buy)","published_at":"2026-10-03T00:15:34.000Z","date":"2026-09-30","kind":"grant","planned":false,"acquired":true,"shares":1322,"price":12.29,"value":16247.38,"ownership":{"direct":true},"footnotes":[{"field":"price","element":"transactionPricePerShare","label":"F2","text":"The options were issued to the Reporting Person pursuant to the Issuer's Amended and Restated Non-Employee Director Compensation Plan in lieu of Board fees."},{"field":"derivative.exercise_date","element":"exerciseDate","label":"F1","text":"The options were granted on September 30, 2026, and are 100% vested."}],"balance_after":1322,"derivative":{"exercise_price":15.33,"expiration_date":"2036-09-30","underlying":"Common Stock","underlying_shares":1322},"source":{"system":"sec-edgar","filing":"0001707797-26-000017","document":"form4-10022026_041020.xml","document_sequence":1,"table":"derivative","row_type":"transaction","position":1,"url":"https://www.sec.gov/Archives/edgar/data/1534120/000170779726000017/form4-10022026_041020.xml","form_type":"4"}},{"id":4635262,"issuer":{"id":4936,"kind":"organization","name":"Avalo Therapeutics, Inc.","symbol":"AVTX"},"owners":[{"id":27193,"kind":"person","name":"Lind Kevin Robert","position":1,"cik":"0001677036","reported_name":"Lind Kevin Robert","relationship":{"director":true,"officer":false,"ten_percent_owner":false,"other":false}}],"security":"Stock Option (Right to Buy)","published_at":"2026-10-03T00:15:31.000Z","date":"2026-09-30","kind":"grant","planned":false,"acquired":true,"shares":1352,"price":12.29,"value":16616.08,"ownership":{"direct":true},"footnotes":[{"field":"price","element":"transactionPricePerShare","label":"F2","text":"The options were issued to the Reporting Person pursuant to the Issuer's Amended and Restated Non-Employee Director Compensation Plan in lieu of Board fees."},{"field":"derivative.exercise_date","element":"exerciseDate","label":"F1","text":"The options were granted on September 30, 2026, and are 100% vested."}],"balance_after":1352,"derivative":{"exercise_price":15.33,"expiration_date":"2036-09-30","underlying":"Common Stock","underlying_shares":1352},"source":{"system":"sec-edgar","filing":"0001677036-26-000009","document":"form4-10022026_041018.xml","document_sequence":1,"table":"derivative","row_type":"transaction","position":1,"url":"https://www.sec.gov/Archives/edgar/data/1534120/000167703626000009/form4-10022026_041018.xml","form_type":"4"}},{"id":4634114,"issuer":{"id":4936,"kind":"organization","name":"Avalo Therapeutics, Inc.","symbol":"AVTX"},"owners":[{"id":33068,"kind":"person","name":"Philip Ron M","position":1,"cik":"0002063957","reported_name":"Philip Ron M","relationship":{"director":true,"officer":false,"ten_percent_owner":false,"other":false}}],"security":"Stock Option (Right to Buy)","published_at":"2026-10-03T00:15:27.000Z","date":"2026-09-30","kind":"grant","planned":false,"acquired":true,"shares":1109,"price":12.29,"value":13629.61,"ownership":{"direct":true},"footnotes":[{"field":"price","element":"transactionPricePerShare","label":"F2","text":"The options were issued to the Reporting Person pursuant to the Issuer's Amended and Restated Non-Employee Director Compensation Plan in lieu of Board fees."},{"field":"derivative.exercise_date","element":"exerciseDate","label":"F1","text":"The options were granted on September 30, 2026, and are 100% vested."}],"balance_after":1109,"derivative":{"exercise_price":15.33,"expiration_date":"2036-09-30","underlying":"Common Stock","underlying_shares":1109},"source":{"system":"sec-edgar","filing":"0002063957-26-000009","document":"form4-10022026_041016.xml","document_sequence":1,"table":"derivative","row_type":"transaction","position":1,"url":"https://www.sec.gov/Archives/edgar/data/2063957/000206395726000009/form4-10022026_041016.xml","form_type":"4"}},{"id":4622856,"issuer":{"id":4936,"kind":"organization","name":"Avalo Therapeutics, Inc.","symbol":"AVTX"},"owners":[{"id":21663,"kind":"person","name":"Sullivan Christopher Ryan","position":1,"cik":"0001810417","reported_name":"Sullivan Christopher Ryan","relationship":{"director":false,"officer":true,"ten_percent_owner":false,"other":false,"officer_title":"Chief Financial Officer"}}],"security":"Stock Option (Right to Buy)","published_at":"2026-09-18T20:10:05.000Z","date":"2026-09-16","kind":"exercise","planned":true,"acquired":false,"shares":12394,"price":0,"value":0.0,"ownership":{"direct":true},"footnotes":[{"field":"kind","element":"transactionCoding","label":"F1","text":"These transactions were effected pursuant to a Rule 10b5-1 trading plan adopted by the Reporting Person on May 18, 2026."},{"field":"derivative.exercise_date","element":"exerciseDate","label":"F3","text":"The stock option vests 25% on March 28, 2025, and 1/36 monthly thereafter, subject to the Reporting Person's continued service on such vesting date."}],"balance_after":83848,"derivative":{"exercise_price":9.88,"expiration_date":"2034-08-13","underlying":"Common Stock","underlying_shares":12394},"source":{"system":"sec-edgar","filing":"0001810417-26-000023","document":"form4-09182026_040901.xml","document_sequence":1,"table":"derivative","row_type":"transaction","position":3,"url":"https://www.sec.gov/Archives/edgar/data/1810417/000181041726000023/form4-09182026_040901.xml","form_type":"4"}},{"id":4622855,"issuer":{"id":4936,"kind":"organization","name":"Avalo Therapeutics, Inc.","symbol":"AVTX"},"owners":[{"id":21663,"kind":"person","name":"Sullivan Christopher Ryan","position":1,"cik":"0001810417","reported_name":"Sullivan Christopher Ryan","relationship":{"director":false,"officer":true,"ten_percent_owner":false,"other":false,"officer_title":"Chief Financial Officer"}}],"security":"Common Stock","published_at":"2026-09-18T20:10:05.000Z","date":"2026-09-16","kind":"sale","planned":true,"acquired":false,"shares":12394,"price":16.3335,"value":202437.399,"ownership":{"direct":true},"footnotes":[{"field":"kind","element":"transactionCoding","label":"F1","text":"These transactions were effected pursuant to a Rule 10b5-1 trading plan adopted by the Reporting Person on May 18, 2026."},{"field":"price","element":"transactionPricePerShare","label":"F2","text":"The reported securities were sold in multiple transactions at prices ranging from $15.91 to $16.65. The Reporting Person undertakes to provide to the Issuer, any security holder of the Issuer or the staff of the Securities and Exchange Commission, upon request, full information regarding the number of shares sold at each separate price within such range."}],"balance_after":39900,"source":{"system":"sec-edgar","filing":"0001810417-26-000023","document":"form4-09182026_040901.xml","document_sequence":1,"table":"nonDerivative","row_type":"transaction","position":2,"url":"https://www.sec.gov/Archives/edgar/data/1810417/000181041726000023/form4-09182026_040901.xml","form_type":"4"}},{"id":4622854,"issuer":{"id":4936,"kind":"organization","name":"Avalo Therapeutics, Inc.","symbol":"AVTX"},"owners":[{"id":21663,"kind":"person","name":"Sullivan Christopher Ryan","position":1,"cik":"0001810417","reported_name":"Sullivan Christopher Ryan","relationship":{"director":false,"officer":true,"ten_percent_owner":false,"other":false,"officer_title":"Chief Financial Officer"}}],"security":"Common Stock","published_at":"2026-09-18T20:10:05.000Z","date":"2026-09-16","kind":"exercise","planned":true,"acquired":true,"shares":12394,"price":9.88,"value":122452.72,"ownership":{"direct":true},"footnotes":[{"field":"kind","element":"transactionCoding","label":"F1","text":"These transactions were effected pursuant to a Rule 10b5-1 trading plan adopted by the Reporting Person on May 18, 2026."}],"balance_after":52294,"source":{"system":"sec-edgar","filing":"0001810417-26-000023","document":"form4-09182026_040901.xml","document_sequence":1,"table":"nonDerivative","row_type":"transaction","position":1,"url":"https://www.sec.gov/Archives/edgar/data/1810417/000181041726000023/form4-09182026_040901.xml","form_type":"4"}},{"id":4615839,"issuer":{"id":4936,"kind":"organization","name":"Avalo Therapeutics, Inc.","symbol":"AVTX"},"owners":[{"id":21663,"kind":"person","name":"Sullivan Christopher Ryan","position":1,"cik":"0001810417","reported_name":"Sullivan Christopher Ryan","relationship":{"director":false,"officer":true,"ten_percent_owner":false,"other":false,"officer_title":"Chief Financial Officer"}}],"security":"Stock Option (Right to Buy)","published_at":"2026-09-11T20:10:06.000Z","date":"2026-09-10","kind":"exercise","planned":true,"acquired":false,"shares":10185,"price":0,"value":0.0,"ownership":{"direct":true},"footnotes":[{"field":"kind","element":"transactionCoding","label":"F1","text":"These transactions were effected pursuant to a Rule 10b5-1 trading plan adopted by the Reporting Person on May 18, 2026."},{"field":"derivative.exercise_date","element":"exerciseDate","label":"F3","text":"The stock option vests twenty-five percent (25%) on January 28, 2026 and the remainder will vest in equal monthly installments over the following three (3) years, subject to the Reporting Person's continued service on such vesting date."}],"balance_after":105815,"derivative":{"exercise_price":8.04,"expiration_date":"2035-01-28","underlying":"Common Stock","underlying_shares":10185},"source":{"system":"sec-edgar","filing":"0001810417-26-000021","document":"form4-09112026_040901.xml","document_sequence":1,"table":"derivative","row_type":"transaction","position":3,"url":"https://www.sec.gov/Archives/edgar/data/1810417/000181041726000021/form4-09112026_040901.xml","form_type":"4"}},{"id":4615838,"issuer":{"id":4936,"kind":"organization","name":"Avalo Therapeutics, Inc.","symbol":"AVTX"},"owners":[{"id":21663,"kind":"person","name":"Sullivan Christopher Ryan","position":1,"cik":"0001810417","reported_name":"Sullivan Christopher Ryan","relationship":{"director":false,"officer":true,"ten_percent_owner":false,"other":false,"officer_title":"Chief Financial Officer"}}],"security":"Common Stock","published_at":"2026-09-11T20:10:06.000Z","date":"2026-09-10","kind":"sale","planned":true,"acquired":false,"shares":10185,"price":17.6197,"value":179456.6445,"ownership":{"direct":true},"footnotes":[{"field":"kind","element":"transactionCoding","label":"F1","text":"These transactions were effected pursuant to a Rule 10b5-1 trading plan adopted by the Reporting Person on May 18, 2026."},{"field":"price","element":"transactionPricePerShare","label":"F2","text":"The reported securities were sold in multiple transactions at prices ranging from $17.17 to $17.95. The Reporting Person undertakes to provide to the Issuer, any security holder of the Issuer or the staff of the Securities and Exchange Commission, upon request, full information regarding the number of shares sold at each separate price within such range."}],"balance_after":39900,"source":{"system":"sec-edgar","filing":"0001810417-26-000021","document":"form4-09112026_040901.xml","document_sequence":1,"table":"nonDerivative","row_type":"transaction","position":2,"url":"https://www.sec.gov/Archives/edgar/data/1810417/000181041726000021/form4-09112026_040901.xml","form_type":"4"}},{"id":4615837,"issuer":{"id":4936,"kind":"organization","name":"Avalo Therapeutics, Inc.","symbol":"AVTX"},"owners":[{"id":21663,"kind":"person","name":"Sullivan Christopher Ryan","position":1,"cik":"0001810417","reported_name":"Sullivan Christopher Ryan","relationship":{"director":false,"officer":true,"ten_percent_owner":false,"other":false,"officer_title":"Chief Financial Officer"}}],"security":"Common Stock","published_at":"2026-09-11T20:10:06.000Z","date":"2026-09-10","kind":"exercise","planned":true,"acquired":true,"shares":10185,"price":8.04,"value":81887.4,"ownership":{"direct":true},"footnotes":[{"field":"kind","element":"transactionCoding","label":"F1","text":"These transactions were effected pursuant to a Rule 10b5-1 trading plan adopted by the Reporting Person on May 18, 2026."}],"balance_after":50085,"source":{"system":"sec-edgar","filing":"0001810417-26-000021","document":"form4-09112026_040901.xml","document_sequence":1,"table":"nonDerivative","row_type":"transaction","position":1,"url":"https://www.sec.gov/Archives/edgar/data/1810417/000181041726000021/form4-09112026_040901.xml","form_type":"4"}},{"id":670895,"issuer":{"id":4936,"kind":"organization","name":"Avalo Therapeutics, Inc.","symbol":"AVTX"},"owners":[{"id":17865,"kind":"person","name":"Doyle Mittie","position":1,"cik":"0001918845","reported_name":"Doyle Mittie","relationship":{"director":false,"officer":true,"ten_percent_owner":false,"other":false,"officer_title":"Chief Medical Officer"}}],"security":"Stock Option (Right to Buy)","published_at":"2026-09-01T20:38:50.000Z","date":"2026-08-28","kind":"exercise","planned":true,"acquired":false,"shares":679,"price":0,"value":0.0,"ownership":{"direct":true},"footnotes":[{"field":"kind","element":"transactionCoding","label":"F1","text":"The transactions reported in this Form 4 were effected pursuant to a Rule 10b5-1 trading plan adopted by the Reporting Person on November 13, 2025."},{"field":"derivative.exercise_date","element":"exerciseDate","label":"F2","text":"The stock option vests twenty-five percent (25%) on January 28, 2026 and the remainder will vest in equal monthly installments over the following three (3) years, subject to the Reporting Person's continued service on each such vesting date."}],"balance_after":113734,"derivative":{"exercise_price":8.04,"expiration_date":"2035-01-28","underlying":"Common Stock","underlying_shares":679},"source":{"system":"sec-edgar","filing":"0001918845-26-000031","document":"form4-09012026_080946.xml","document_sequence":1,"table":"derivative","row_type":"transaction","position":3,"url":"https://www.sec.gov/Archives/edgar/data/1534120/000191884526000031/form4-09012026_080946.xml","form_type":"4"}},{"id":670894,"issuer":{"id":4936,"kind":"organization","name":"Avalo Therapeutics, Inc.","symbol":"AVTX"},"owners":[{"id":17865,"kind":"person","name":"Doyle Mittie","position":1,"cik":"0001918845","reported_name":"Doyle Mittie","relationship":{"director":false,"officer":true,"ten_percent_owner":false,"other":false,"officer_title":"Chief Medical Officer"}}],"security":"Common Stock","published_at":"2026-09-01T20:38:50.000Z","date":"2026-08-28","kind":"sale","planned":true,"acquired":false,"shares":679,"price":20,"value":13580.0,"ownership":{"direct":true},"footnotes":[{"field":"kind","element":"transactionCoding","label":"F1","text":"The transactions reported in this Form 4 were effected pursuant to a Rule 10b5-1 trading plan adopted by the Reporting Person on November 13, 2025."}],"balance_after":51776,"source":{"system":"sec-edgar","filing":"0001918845-26-000031","document":"form4-09012026_080946.xml","document_sequence":1,"table":"nonDerivative","row_type":"transaction","position":2,"url":"https://www.sec.gov/Archives/edgar/data/1534120/000191884526000031/form4-09012026_080946.xml","form_type":"4"}},{"id":670893,"issuer":{"id":4936,"kind":"organization","name":"Avalo Therapeutics, Inc.","symbol":"AVTX"},"owners":[{"id":17865,"kind":"person","name":"Doyle Mittie","position":1,"cik":"0001918845","reported_name":"Doyle Mittie","relationship":{"director":false,"officer":true,"ten_percent_owner":false,"other":false,"officer_title":"Chief Medical Officer"}}],"security":"Common Stock","published_at":"2026-09-01T20:38:50.000Z","date":"2026-08-28","kind":"exercise","planned":true,"acquired":true,"shares":679,"price":8.04,"value":5459.16,"ownership":{"direct":true},"footnotes":[{"field":"kind","element":"transactionCoding","label":"F1","text":"The transactions reported in this Form 4 were effected pursuant to a Rule 10b5-1 trading plan adopted by the Reporting Person on November 13, 2025."}],"balance_after":52455,"source":{"system":"sec-edgar","filing":"0001918845-26-000031","document":"form4-09012026_080946.xml","document_sequence":1,"table":"nonDerivative","row_type":"transaction","position":1,"url":"https://www.sec.gov/Archives/edgar/data/1534120/000191884526000031/form4-09012026_080946.xml","form_type":"4"}},{"id":681494,"issuer":{"id":4936,"kind":"organization","name":"Avalo Therapeutics, Inc.","symbol":"AVTX"},"owners":[{"id":21663,"kind":"person","name":"Sullivan Christopher Ryan","position":1,"cik":"0001810417","reported_name":"Sullivan Christopher Ryan","relationship":{"director":false,"officer":true,"ten_percent_owner":false,"other":false,"officer_title":"Chief Financial Officer"}}],"security":"Stock Option (Right to Buy)","published_at":"2026-08-19T20:10:18.000Z","date":"2026-08-18","kind":"exercise","planned":true,"acquired":false,"shares":31031,"price":0,"value":0.0,"ownership":{"direct":true},"footnotes":[{"field":"derivative.exercise_date","element":"exerciseDate","label":"F5","text":"The stock option vests 25% on March 28, 2025, and 1/36 monthly thereafter, subject to the Reporting Person's continued service on such vesting date."}],"balance_after":96242,"derivative":{"exercise_price":9.88,"expiration_date":"2034-08-13","underlying":"Common Stock","underlying_shares":31031},"source":{"system":"sec-edgar","filing":"0001810417-26-000019","document":"form4-08192026_040813.xml","document_sequence":1,"table":"derivative","row_type":"transaction","position":9,"url":"https://www.sec.gov/Archives/edgar/data/1810417/000181041726000019/form4-08192026_040813.xml","form_type":"4"}},{"id":681493,"issuer":{"id":4936,"kind":"organization","name":"Avalo Therapeutics, Inc.","symbol":"AVTX"},"owners":[{"id":21663,"kind":"person","name":"Sullivan Christopher Ryan","position":1,"cik":"0001810417","reported_name":"Sullivan Christopher Ryan","relationship":{"director":false,"officer":true,"ten_percent_owner":false,"other":false,"officer_title":"Chief Financial Officer"}}],"security":"Stock Option (Right to Buy)","published_at":"2026-08-19T20:10:18.000Z","date":"2026-08-17","kind":"exercise","planned":true,"acquired":false,"shares":2876,"price":0,"value":0.0,"ownership":{"direct":true},"footnotes":[{"field":"derivative.exercise_date","element":"exerciseDate","label":"F5","text":"The stock option vests 25% on March 28, 2025, and 1/36 monthly thereafter, subject to the Reporting Person's continued service on such vesting date."}],"balance_after":127273,"derivative":{"exercise_price":9.88,"expiration_date":"2034-08-13","underlying":"Common Stock","underlying_shares":2876},"source":{"system":"sec-edgar","filing":"0001810417-26-000019","document":"form4-08192026_040813.xml","document_sequence":1,"table":"derivative","row_type":"transaction","position":8,"url":"https://www.sec.gov/Archives/edgar/data/1810417/000181041726000019/form4-08192026_040813.xml","form_type":"4"}},{"id":681492,"issuer":{"id":4936,"kind":"organization","name":"Avalo Therapeutics, Inc.","symbol":"AVTX"},"owners":[{"id":21663,"kind":"person","name":"Sullivan Christopher Ryan","position":1,"cik":"0001810417","reported_name":"Sullivan Christopher Ryan","relationship":{"director":false,"officer":true,"ten_percent_owner":false,"other":false,"officer_title":"Chief Financial Officer"}}],"security":"Stock Option (Right to Buy)","published_at":"2026-08-19T20:10:18.000Z","date":"2026-08-17","kind":"exercise","planned":true,"acquired":false,"shares":37945,"price":0,"value":0.0,"ownership":{"direct":true},"footnotes":[{"field":"kind","element":"transactionCoding","label":"F1","text":"These transactions were effected pursuant to a Rule 10b5-1 trading plan adopted by the Reporting Person on May 18, 2026."},{"field":"derivative.exercise_date","element":"exerciseDate","label":"F5","text":"The stock option vests 25% on March 28, 2025, and 1/36 monthly thereafter, subject to the Reporting Person's continued service on such vesting date."}],"balance_after":130149,"derivative":{"exercise_price":9.88,"expiration_date":"2034-08-13","underlying":"Common Stock","underlying_shares":37945},"source":{"system":"sec-edgar","filing":"0001810417-26-000019","document":"form4-08192026_040813.xml","document_sequence":1,"table":"derivative","row_type":"transaction","position":7,"url":"https://www.sec.gov/Archives/edgar/data/1810417/000181041726000019/form4-08192026_040813.xml","form_type":"4"}},{"id":681491,"issuer":{"id":4936,"kind":"organization","name":"Avalo Therapeutics, Inc.","symbol":"AVTX"},"owners":[{"id":21663,"kind":"person","name":"Sullivan Christopher Ryan","position":1,"cik":"0001810417","reported_name":"Sullivan Christopher Ryan","relationship":{"director":false,"officer":true,"ten_percent_owner":false,"other":false,"officer_title":"Chief Financial Officer"}}],"security":"Common Stock","published_at":"2026-08-19T20:10:18.000Z","date":"2026-08-18","kind":"sale","planned":true,"acquired":false,"shares":31031,"price":20.0549,"value":622323.6019,"ownership":{"direct":true},"footnotes":[{"field":"price","element":"transactionPricePerShare","label":"F4","text":"The reported securities were sold in multiple transactions at prices ranging from $20.00 to $20.265. The Reporting Person undertakes to provide to the Issuer, any security holder of the Issuer or the staff of the Securities and Exchange Commission, upon request, full information regarding the number of shares sold at each separate price within such range."}],"balance_after":39900,"source":{"system":"sec-edgar","filing":"0001810417-26-000019","document":"form4-08192026_040813.xml","document_sequence":1,"table":"nonDerivative","row_type":"transaction","position":6,"url":"https://www.sec.gov/Archives/edgar/data/1810417/000181041726000019/form4-08192026_040813.xml","form_type":"4"}},{"id":681490,"issuer":{"id":4936,"kind":"organization","name":"Avalo Therapeutics, Inc.","symbol":"AVTX"},"owners":[{"id":21663,"kind":"person","name":"Sullivan Christopher Ryan","position":1,"cik":"0001810417","reported_name":"Sullivan Christopher Ryan","relationship":{"director":false,"officer":true,"ten_percent_owner":false,"other":false,"officer_title":"Chief Financial Officer"}}],"security":"Common Stock","published_at":"2026-08-19T20:10:18.000Z","date":"2026-08-18","kind":"exercise","planned":true,"acquired":true,"shares":31031,"price":9.88,"value":306586.28,"ownership":{"direct":true},"balance_after":70931,"source":{"system":"sec-edgar","filing":"0001810417-26-000019","document":"form4-08192026_040813.xml","document_sequence":1,"table":"nonDerivative","row_type":"transaction","position":5,"url":"https://www.sec.gov/Archives/edgar/data/1810417/000181041726000019/form4-08192026_040813.xml","form_type":"4"}},{"id":681489,"issuer":{"id":4936,"kind":"organization","name":"Avalo Therapeutics, Inc.","symbol":"AVTX"},"owners":[{"id":21663,"kind":"person","name":"Sullivan Christopher Ryan","position":1,"cik":"0001810417","reported_name":"Sullivan Christopher Ryan","relationship":{"director":false,"officer":true,"ten_percent_owner":false,"other":false,"officer_title":"Chief Financial Officer"}}],"security":"Common Stock","published_at":"2026-08-19T20:10:18.000Z","date":"2026-08-17","kind":"sale","planned":true,"acquired":false,"shares":3749,"price":19.9419,"value":74762.1831,"ownership":{"direct":true},"footnotes":[{"field":"price","element":"transactionPricePerShare","label":"F3","text":"The reported securities were sold in multiple transactions at prices ranging from $19.70 to $20.02. The Reporting Person undertakes to provide to the Issuer, any security holder of the Issuer or the staff of the Securities and Exchange Commission, upon request, full information regarding the number of shares sold at each separate price within such range."}],"balance_after":39900,"source":{"system":"sec-edgar","filing":"0001810417-26-000019","document":"form4-08192026_040813.xml","document_sequence":1,"table":"nonDerivative","row_type":"transaction","position":4,"url":"https://www.sec.gov/Archives/edgar/data/1810417/000181041726000019/form4-08192026_040813.xml","form_type":"4"}},{"id":681488,"issuer":{"id":4936,"kind":"organization","name":"Avalo Therapeutics, Inc.","symbol":"AVTX"},"owners":[{"id":21663,"kind":"person","name":"Sullivan Christopher Ryan","position":1,"cik":"0001810417","reported_name":"Sullivan Christopher Ryan","relationship":{"director":false,"officer":true,"ten_percent_owner":false,"other":false,"officer_title":"Chief Financial Officer"}}],"security":"Common Stock","published_at":"2026-08-19T20:10:18.000Z","date":"2026-08-17","kind":"sale","planned":true,"acquired":false,"shares":37945,"price":19.8533,"value":753333.4685,"ownership":{"direct":true},"footnotes":[{"field":"kind","element":"transactionCoding","label":"F1","text":"These transactions were effected pursuant to a Rule 10b5-1 trading plan adopted by the Reporting Person on May 18, 2026."},{"field":"price","element":"transactionPricePerShare","label":"F2","text":"The reported securities were sold in multiple transactions at prices ranging from $19.16 to $20.02. The Reporting Person undertakes to provide to the Issuer, any security holder of the Issuer or the staff of the Securities and Exchange Commission, upon request, full information regarding the number of shares sold at each separate price within such range."}],"balance_after":43649,"source":{"system":"sec-edgar","filing":"0001810417-26-000019","document":"form4-08192026_040813.xml","document_sequence":1,"table":"nonDerivative","row_type":"transaction","position":3,"url":"https://www.sec.gov/Archives/edgar/data/1810417/000181041726000019/form4-08192026_040813.xml","form_type":"4"}},{"id":681487,"issuer":{"id":4936,"kind":"organization","name":"Avalo Therapeutics, Inc.","symbol":"AVTX"},"owners":[{"id":21663,"kind":"person","name":"Sullivan Christopher Ryan","position":1,"cik":"0001810417","reported_name":"Sullivan Christopher Ryan","relationship":{"director":false,"officer":true,"ten_percent_owner":false,"other":false,"officer_title":"Chief Financial Officer"}}],"security":"Common Stock","published_at":"2026-08-19T20:10:18.000Z","date":"2026-08-17","kind":"exercise","planned":true,"acquired":true,"shares":2876,"price":9.88,"value":28414.88,"ownership":{"direct":true},"balance_after":81594,"source":{"system":"sec-edgar","filing":"0001810417-26-000019","document":"form4-08192026_040813.xml","document_sequence":1,"table":"nonDerivative","row_type":"transaction","position":2,"url":"https://www.sec.gov/Archives/edgar/data/1810417/000181041726000019/form4-08192026_040813.xml","form_type":"4"}},{"id":681486,"issuer":{"id":4936,"kind":"organization","name":"Avalo Therapeutics, Inc.","symbol":"AVTX"},"owners":[{"id":21663,"kind":"person","name":"Sullivan Christopher Ryan","position":1,"cik":"0001810417","reported_name":"Sullivan Christopher Ryan","relationship":{"director":false,"officer":true,"ten_percent_owner":false,"other":false,"officer_title":"Chief Financial Officer"}}],"security":"Common Stock","published_at":"2026-08-19T20:10:18.000Z","date":"2026-08-17","kind":"exercise","planned":true,"acquired":true,"shares":37945,"price":9.88,"value":374896.6,"ownership":{"direct":true},"footnotes":[{"field":"kind","element":"transactionCoding","label":"F1","text":"These transactions were effected pursuant to a Rule 10b5-1 trading plan adopted by the Reporting Person on May 18, 2026."}],"balance_after":78718,"source":{"system":"sec-edgar","filing":"0001810417-26-000019","document":"form4-08192026_040813.xml","document_sequence":1,"table":"nonDerivative","row_type":"transaction","position":1,"url":"https://www.sec.gov/Archives/edgar/data/1810417/000181041726000019/form4-08192026_040813.xml","form_type":"4"}},{"id":681053,"issuer":{"id":4936,"kind":"organization","name":"Avalo Therapeutics, Inc.","symbol":"AVTX"},"owners":[{"id":17865,"kind":"person","name":"Doyle Mittie","position":1,"cik":"0001918845","reported_name":"Doyle Mittie","relationship":{"director":false,"officer":true,"ten_percent_owner":false,"other":false,"officer_title":"Chief Medical Officer"}}],"security":"Stock Option (Right to Buy)","published_at":"2026-08-19T20:10:15.000Z","date":"2026-08-17","kind":"exercise","planned":true,"acquired":false,"shares":1000,"price":0,"value":0.0,"ownership":{"direct":true},"footnotes":[{"field":"kind","element":"transactionCoding","label":"F1","text":"The transactions reported in this Form 4 were effected pursuant to a Rule 10b5-1 trading plan adopted by the Reporting Person on November 13, 2025."},{"field":"derivative.exercise_date","element":"exerciseDate","label":"F2","text":"The stock option vests twenty-five percent (25%) on July 15, 2025 and the remainder will vest in equal monthly installments over the following three (3) years, subject to the Reporting Person's continued service on each such vesting date."}],"balance_after":123750,"derivative":{"exercise_price":12.65,"expiration_date":"2034-07-15","underlying":"Common Stock","underlying_shares":1000},"source":{"system":"sec-edgar","filing":"0001918845-26-000029","document":"form4-08192026_040810.xml","document_sequence":1,"table":"derivative","row_type":"transaction","position":3,"url":"https://www.sec.gov/Archives/edgar/data/1534120/000191884526000029/form4-08192026_040810.xml","form_type":"4"}},{"id":681052,"issuer":{"id":4936,"kind":"organization","name":"Avalo Therapeutics, Inc.","symbol":"AVTX"},"owners":[{"id":17865,"kind":"person","name":"Doyle Mittie","position":1,"cik":"0001918845","reported_name":"Doyle Mittie","relationship":{"director":false,"officer":true,"ten_percent_owner":false,"other":false,"officer_title":"Chief Medical Officer"}}],"security":"Common Stock","published_at":"2026-08-19T20:10:15.000Z","date":"2026-08-17","kind":"sale","planned":true,"acquired":false,"shares":1000,"price":20,"value":20000.0,"ownership":{"direct":true},"footnotes":[{"field":"kind","element":"transactionCoding","label":"F1","text":"The transactions reported in this Form 4 were effected pursuant to a Rule 10b5-1 trading plan adopted by the Reporting Person on November 13, 2025."}],"balance_after":51776,"source":{"system":"sec-edgar","filing":"0001918845-26-000029","document":"form4-08192026_040810.xml","document_sequence":1,"table":"nonDerivative","row_type":"transaction","position":2,"url":"https://www.sec.gov/Archives/edgar/data/1534120/000191884526000029/form4-08192026_040810.xml","form_type":"4"}},{"id":681051,"issuer":{"id":4936,"kind":"organization","name":"Avalo Therapeutics, Inc.","symbol":"AVTX"},"owners":[{"id":17865,"kind":"person","name":"Doyle Mittie","position":1,"cik":"0001918845","reported_name":"Doyle Mittie","relationship":{"director":false,"officer":true,"ten_percent_owner":false,"other":false,"officer_title":"Chief Medical Officer"}}],"security":"Common Stock","published_at":"2026-08-19T20:10:15.000Z","date":"2026-08-17","kind":"exercise","planned":true,"acquired":true,"shares":1000,"price":12.65,"value":12650.0,"ownership":{"direct":true},"footnotes":[{"field":"kind","element":"transactionCoding","label":"F1","text":"The transactions reported in this Form 4 were effected pursuant to a Rule 10b5-1 trading plan adopted by the Reporting Person on November 13, 2025."}],"balance_after":52776,"source":{"system":"sec-edgar","filing":"0001918845-26-000029","document":"form4-08192026_040810.xml","document_sequence":1,"table":"nonDerivative","row_type":"transaction","position":1,"url":"https://www.sec.gov/Archives/edgar/data/1534120/000191884526000029/form4-08192026_040810.xml","form_type":"4"}},{"id":689522,"issuer":{"id":4936,"kind":"organization","name":"Avalo Therapeutics, Inc.","symbol":"AVTX"},"owners":[{"id":24237,"kind":"person","name":"Riley Jennifer","position":1,"cik":"0002047607","reported_name":"Riley Jennifer","relationship":{"director":false,"officer":true,"ten_percent_owner":false,"other":false,"officer_title":"Chief Strategy Officer"}}],"security":"Common Stock","published_at":"2026-08-12T20:10:17.000Z","date":"2026-08-11","kind":"sale","planned":false,"acquired":false,"shares":2655,"price":19.5903,"value":52012.2465,"ownership":{"direct":true},"footnotes":[{"field":"price","element":"transactionPricePerShare","label":"F1","text":"The price reported in Column 4 is a weighted average price. These shares were sold in multiple transactions at prices ranging from $19.54 to $19.65, inclusive. The Reporting Person undertakes to provide to the Issuer, any security holder of the Issuer, or the staff of the Securities and Exchange Commission, upon request, full information regarding the number of shares sold at each separate price within the range."}],"balance_after":37041,"source":{"system":"sec-edgar","filing":"0002047607-26-000008","document":"form4-08122026_040809.xml","document_sequence":1,"table":"nonDerivative","row_type":"transaction","position":1,"url":"https://www.sec.gov/Archives/edgar/data/2047607/000204760726000008/form4-08122026_040809.xml","form_type":"4"}},{"id":689000,"issuer":{"id":4936,"kind":"organization","name":"Avalo Therapeutics, Inc.","symbol":"AVTX"},"owners":[{"id":17865,"kind":"person","name":"Doyle Mittie","position":1,"cik":"0001918845","reported_name":"Doyle Mittie","relationship":{"director":false,"officer":true,"ten_percent_owner":false,"other":false,"officer_title":"Chief Medical Officer"}}],"security":"Stock Option (Right to Buy)","published_at":"2026-08-12T20:10:11.000Z","date":"2026-08-10","kind":"exercise","planned":true,"acquired":false,"shares":679,"price":0,"value":0.0,"ownership":{"direct":true},"footnotes":[{"field":"kind","element":"transactionCoding","label":"F1","text":"The transactions reported in this Form 4 were effected pursuant to a Rule 10b5-1 trading plan adopted by the Reporting Person on November 13, 2025."},{"field":"derivative.exercise_date","element":"exerciseDate","label":"F2","text":"The stock option vests twenty-five percent (25%) on January 28, 2026 and the remainder will vest in equal monthly installments over the following three (3) years, subject to the Reporting Person's continued service on each such vesting date."}],"balance_after":114413,"derivative":{"exercise_price":8.04,"expiration_date":"2035-01-28","underlying":"Common Stock","underlying_shares":679},"source":{"system":"sec-edgar","filing":"0001918845-26-000026","document":"form4-08122026_040801.xml","document_sequence":1,"table":"derivative","row_type":"transaction","position":3,"url":"https://www.sec.gov/Archives/edgar/data/1534120/000191884526000026/form4-08122026_040801.xml","form_type":"4"}},{"id":688999,"issuer":{"id":4936,"kind":"organization","name":"Avalo Therapeutics, Inc.","symbol":"AVTX"},"owners":[{"id":17865,"kind":"person","name":"Doyle Mittie","position":1,"cik":"0001918845","reported_name":"Doyle Mittie","relationship":{"director":false,"officer":true,"ten_percent_owner":false,"other":false,"officer_title":"Chief Medical Officer"}}],"security":"Common Stock","published_at":"2026-08-12T20:10:11.000Z","date":"2026-08-10","kind":"sale","planned":true,"acquired":false,"shares":679,"price":20,"value":13580.0,"ownership":{"direct":true},"footnotes":[{"field":"kind","element":"transactionCoding","label":"F1","text":"The transactions reported in this Form 4 were effected pursuant to a Rule 10b5-1 trading plan adopted by the Reporting Person on November 13, 2025."}],"balance_after":51776,"source":{"system":"sec-edgar","filing":"0001918845-26-000026","document":"form4-08122026_040801.xml","document_sequence":1,"table":"nonDerivative","row_type":"transaction","position":2,"url":"https://www.sec.gov/Archives/edgar/data/1534120/000191884526000026/form4-08122026_040801.xml","form_type":"4"}},{"id":688998,"issuer":{"id":4936,"kind":"organization","name":"Avalo Therapeutics, Inc.","symbol":"AVTX"},"owners":[{"id":17865,"kind":"person","name":"Doyle Mittie","position":1,"cik":"0001918845","reported_name":"Doyle Mittie","relationship":{"director":false,"officer":true,"ten_percent_owner":false,"other":false,"officer_title":"Chief Medical Officer"}}],"security":"Common Stock","published_at":"2026-08-12T20:10:11.000Z","date":"2026-08-10","kind":"exercise","planned":true,"acquired":true,"shares":679,"price":8.04,"value":5459.16,"ownership":{"direct":true},"footnotes":[{"field":"kind","element":"transactionCoding","label":"F1","text":"The transactions reported in this Form 4 were effected pursuant to a Rule 10b5-1 trading plan adopted by the Reporting Person on November 13, 2025."}],"balance_after":52455,"source":{"system":"sec-edgar","filing":"0001918845-26-000026","document":"form4-08122026_040801.xml","document_sequence":1,"table":"nonDerivative","row_type":"transaction","position":1,"url":"https://www.sec.gov/Archives/edgar/data/1534120/000191884526000026/form4-08122026_040801.xml","form_type":"4"}},{"id":701355,"issuer":{"id":4936,"kind":"organization","name":"Avalo Therapeutics, Inc.","symbol":"AVTX"},"owners":[{"id":17865,"kind":"person","name":"Doyle Mittie","position":1,"cik":"0001918845","reported_name":"Doyle Mittie","relationship":{"director":false,"officer":true,"ten_percent_owner":false,"other":false,"officer_title":"Chief Medical Officer"}}],"security":"Stock Option (Right to Buy)","published_at":"2026-07-29T20:05:05.000Z","date":"2026-07-27","kind":"exercise","planned":true,"acquired":false,"shares":1000,"price":0,"value":0.0,"ownership":{"direct":true},"footnotes":[{"field":"kind","element":"transactionCoding","label":"F1","text":"The transactions reported in this Form 4 were effected pursuant to a Rule 10b5-1 trading plan adopted by the Reporting Person on November 13, 2025."},{"field":"derivative.exercise_date","element":"exerciseDate","label":"F2","text":"The stock option vests twenty-five percent (25%) on July 15, 2025 and the remainder will vest in equal monthly installments over the following three (3) years, subject to the Reporting Person's continued service on each such vesting date."}],"balance_after":124750,"derivative":{"exercise_price":12.65,"expiration_date":"2034-07-15","underlying":"Common Stock","underlying_shares":1000},"source":{"system":"sec-edgar","filing":"0001918845-26-000024","document":"form4-07292026_040701.xml","document_sequence":1,"table":"derivative","row_type":"transaction","position":3,"url":"https://www.sec.gov/Archives/edgar/data/1534120/000191884526000024/form4-07292026_040701.xml","form_type":"4"}},{"id":701354,"issuer":{"id":4936,"kind":"organization","name":"Avalo Therapeutics, Inc.","symbol":"AVTX"},"owners":[{"id":17865,"kind":"person","name":"Doyle Mittie","position":1,"cik":"0001918845","reported_name":"Doyle Mittie","relationship":{"director":false,"officer":true,"ten_percent_owner":false,"other":false,"officer_title":"Chief Medical Officer"}}],"security":"Common Stock","published_at":"2026-07-29T20:05:05.000Z","date":"2026-07-27","kind":"sale","planned":true,"acquired":false,"shares":1000,"price":20,"value":20000.0,"ownership":{"direct":true},"footnotes":[{"field":"kind","element":"transactionCoding","label":"F1","text":"The transactions reported in this Form 4 were effected pursuant to a Rule 10b5-1 trading plan adopted by the Reporting Person on November 13, 2025."}],"balance_after":51776,"source":{"system":"sec-edgar","filing":"0001918845-26-000024","document":"form4-07292026_040701.xml","document_sequence":1,"table":"nonDerivative","row_type":"transaction","position":2,"url":"https://www.sec.gov/Archives/edgar/data/1534120/000191884526000024/form4-07292026_040701.xml","form_type":"4"}},{"id":701353,"issuer":{"id":4936,"kind":"organization","name":"Avalo Therapeutics, Inc.","symbol":"AVTX"},"owners":[{"id":17865,"kind":"person","name":"Doyle Mittie","position":1,"cik":"0001918845","reported_name":"Doyle Mittie","relationship":{"director":false,"officer":true,"ten_percent_owner":false,"other":false,"officer_title":"Chief Medical Officer"}}],"security":"Common Stock","published_at":"2026-07-29T20:05:05.000Z","date":"2026-07-27","kind":"exercise","planned":true,"acquired":true,"shares":1000,"price":12.65,"value":12650.0,"ownership":{"direct":true},"footnotes":[{"field":"kind","element":"transactionCoding","label":"F1","text":"The transactions reported in this Form 4 were effected pursuant to a Rule 10b5-1 trading plan adopted by the Reporting Person on November 13, 2025."}],"balance_after":52776,"source":{"system":"sec-edgar","filing":"0001918845-26-000024","document":"form4-07292026_040701.xml","document_sequence":1,"table":"nonDerivative","row_type":"transaction","position":1,"url":"https://www.sec.gov/Archives/edgar/data/1534120/000191884526000024/form4-07292026_040701.xml","form_type":"4"}},{"id":717308,"issuer":{"id":4936,"kind":"organization","name":"Avalo Therapeutics, Inc.","symbol":"AVTX"},"owners":[{"id":17865,"kind":"person","name":"Doyle Mittie","position":1,"cik":"0001918845","reported_name":"Doyle Mittie","relationship":{"director":false,"officer":true,"ten_percent_owner":false,"other":false,"officer_title":"Chief Medical Officer"}}],"security":"Stock Option (Right to Buy)","published_at":"2026-07-02T20:05:31.000Z","date":"2026-06-30","kind":"exercise","planned":true,"acquired":false,"shares":1779,"price":0,"value":0.0,"ownership":{"direct":true},"footnotes":[{"field":"kind","element":"transactionCoding","label":"F1","text":"The transactions reported in this Form 4 were effected pursuant to a Rule 10b5-1 trading plan adopted by the Reporting Person on November 13, 2025."},{"field":"derivative.exercise_date","element":"exerciseDate","label":"F3","text":"The stock option vests twenty-five percent (25%) on January 28, 2026 and the remainder will vest in equal monthly installments over the following three (3) years, subject to the Reporting Person's continued service on each such vesting date."}],"balance_after":115092,"derivative":{"exercise_price":8.04,"expiration_date":"2035-01-28","underlying":"Common Stock","underlying_shares":1779},"source":{"system":"sec-edgar","filing":"0001918845-26-000022","document":"form4-07022026_040722.xml","document_sequence":1,"table":"derivative","row_type":"transaction","position":5,"url":"https://www.sec.gov/Archives/edgar/data/1534120/000191884526000022/form4-07022026_040722.xml","form_type":"4"}},{"id":717307,"issuer":{"id":4936,"kind":"organization","name":"Avalo Therapeutics, Inc.","symbol":"AVTX"},"owners":[{"id":17865,"kind":"person","name":"Doyle Mittie","position":1,"cik":"0001918845","reported_name":"Doyle Mittie","relationship":{"director":false,"officer":true,"ten_percent_owner":false,"other":false,"officer_title":"Chief Medical Officer"}}],"security":"Stock Option (Right to Buy)","published_at":"2026-07-02T20:05:31.000Z","date":"2026-06-30","kind":"exercise","planned":true,"acquired":false,"shares":2875,"price":0,"value":0.0,"ownership":{"direct":true},"footnotes":[{"field":"kind","element":"transactionCoding","label":"F1","text":"The transactions reported in this Form 4 were effected pursuant to a Rule 10b5-1 trading plan adopted by the Reporting Person on November 13, 2025."},{"field":"derivative.exercise_date","element":"exerciseDate","label":"F2","text":"The stock option vests twenty-five percent (25%) on July 15, 2025 and the remainder will vest in equal monthly installments over the following three (3) years, subject to the Reporting Person's continued service on each such vesting date."}],"balance_after":125750,"derivative":{"exercise_price":12.65,"expiration_date":"2034-07-15","underlying":"Common Stock","underlying_shares":2875},"source":{"system":"sec-edgar","filing":"0001918845-26-000022","document":"form4-07022026_040722.xml","document_sequence":1,"table":"derivative","row_type":"transaction","position":4,"url":"https://www.sec.gov/Archives/edgar/data/1534120/000191884526000022/form4-07022026_040722.xml","form_type":"4"}},{"id":717306,"issuer":{"id":4936,"kind":"organization","name":"Avalo Therapeutics, Inc.","symbol":"AVTX"},"owners":[{"id":17865,"kind":"person","name":"Doyle Mittie","position":1,"cik":"0001918845","reported_name":"Doyle Mittie","relationship":{"director":false,"officer":true,"ten_percent_owner":false,"other":false,"officer_title":"Chief Medical Officer"}}],"security":"Common Stock","published_at":"2026-07-02T20:05:31.000Z","date":"2026-06-30","kind":"sale","planned":true,"acquired":false,"shares":4654,"price":20,"value":93080.0,"ownership":{"direct":true},"footnotes":[{"field":"kind","element":"transactionCoding","label":"F1","text":"The transactions reported in this Form 4 were effected pursuant to a Rule 10b5-1 trading plan adopted by the Reporting Person on November 13, 2025."}],"balance_after":51776,"source":{"system":"sec-edgar","filing":"0001918845-26-000022","document":"form4-07022026_040722.xml","document_sequence":1,"table":"nonDerivative","row_type":"transaction","position":3,"url":"https://www.sec.gov/Archives/edgar/data/1534120/000191884526000022/form4-07022026_040722.xml","form_type":"4"}},{"id":717305,"issuer":{"id":4936,"kind":"organization","name":"Avalo Therapeutics, Inc.","symbol":"AVTX"},"owners":[{"id":17865,"kind":"person","name":"Doyle Mittie","position":1,"cik":"0001918845","reported_name":"Doyle Mittie","relationship":{"director":false,"officer":true,"ten_percent_owner":false,"other":false,"officer_title":"Chief Medical Officer"}}],"security":"Common Stock","published_at":"2026-07-02T20:05:31.000Z","date":"2026-06-30","kind":"exercise","planned":true,"acquired":true,"shares":1779,"price":8.04,"value":14303.16,"ownership":{"direct":true},"footnotes":[{"field":"kind","element":"transactionCoding","label":"F1","text":"The transactions reported in this Form 4 were effected pursuant to a Rule 10b5-1 trading plan adopted by the Reporting Person on November 13, 2025."}],"balance_after":56430,"source":{"system":"sec-edgar","filing":"0001918845-26-000022","document":"form4-07022026_040722.xml","document_sequence":1,"table":"nonDerivative","row_type":"transaction","position":2,"url":"https://www.sec.gov/Archives/edgar/data/1534120/000191884526000022/form4-07022026_040722.xml","form_type":"4"}},{"id":717304,"issuer":{"id":4936,"kind":"organization","name":"Avalo Therapeutics, Inc.","symbol":"AVTX"},"owners":[{"id":17865,"kind":"person","name":"Doyle Mittie","position":1,"cik":"0001918845","reported_name":"Doyle Mittie","relationship":{"director":false,"officer":true,"ten_percent_owner":false,"other":false,"officer_title":"Chief Medical Officer"}}],"security":"Common Stock","published_at":"2026-07-02T20:05:31.000Z","date":"2026-06-30","kind":"exercise","planned":true,"acquired":true,"shares":2875,"price":12.65,"value":36368.75,"ownership":{"direct":true},"footnotes":[{"field":"kind","element":"transactionCoding","label":"F1","text":"The transactions reported in this Form 4 were effected pursuant to a Rule 10b5-1 trading plan adopted by the Reporting Person on November 13, 2025."}],"balance_after":54651,"source":{"system":"sec-edgar","filing":"0001918845-26-000022","document":"form4-07022026_040722.xml","document_sequence":1,"table":"nonDerivative","row_type":"transaction","position":1,"url":"https://www.sec.gov/Archives/edgar/data/1534120/000191884526000022/form4-07022026_040722.xml","form_type":"4"}},{"id":718699,"issuer":{"id":4936,"kind":"organization","name":"Avalo Therapeutics, Inc.","symbol":"AVTX"},"owners":[{"id":33068,"kind":"person","name":"Philip Ron M","position":1,"cik":"0002063957","reported_name":"Philip Ron M","relationship":{"director":true,"officer":false,"ten_percent_owner":false,"other":false}}],"security":"Stock Option (Right to Buy)","published_at":"2026-07-02T20:05:29.000Z","date":"2026-06-30","kind":"grant","planned":false,"acquired":true,"shares":69,"price":15.04,"value":1037.76,"ownership":{"direct":true},"footnotes":[{"field":"derivative.exercise_date","element":"exerciseDate","label":"F1","text":"The options were granted on June 30, 2026, and are 100% vested."}],"balance_after":69,"derivative":{"exercise_price":18.48,"expiration_date":"2036-06-30","underlying":"Common Stock","underlying_shares":69},"source":{"system":"sec-edgar","filing":"0002063957-26-000007","document":"form4-07022026_040721.xml","document_sequence":1,"table":"derivative","row_type":"transaction","position":1,"url":"https://www.sec.gov/Archives/edgar/data/2063957/000206395726000007/form4-07022026_040721.xml","form_type":"4"}},{"id":717300,"issuer":{"id":4936,"kind":"organization","name":"Avalo Therapeutics, Inc.","symbol":"AVTX"},"owners":[{"id":27193,"kind":"person","name":"Lind Kevin Robert","position":1,"cik":"0001677036","reported_name":"Lind Kevin Robert","relationship":{"director":true,"officer":false,"ten_percent_owner":false,"other":false}}],"security":"Stock Option (Right to Buy)","published_at":"2026-07-02T20:05:28.000Z","date":"2026-06-30","kind":"grant","planned":false,"acquired":true,"shares":1105,"price":15.04,"value":16619.2,"ownership":{"direct":true},"footnotes":[{"field":"derivative.exercise_date","element":"exerciseDate","label":"F1","text":"The options were granted on June 30, 2026, and are 100% vested."}],"balance_after":1105,"derivative":{"exercise_price":18.48,"expiration_date":"2036-06-30","underlying":"Common Stock","underlying_shares":1105},"source":{"system":"sec-edgar","filing":"0001677036-26-000006","document":"form4-07022026_040719.xml","document_sequence":1,"table":"derivative","row_type":"transaction","position":1,"url":"https://www.sec.gov/Archives/edgar/data/1534120/000167703626000006/form4-07022026_040719.xml","form_type":"4"}},{"id":717299,"issuer":{"id":4936,"kind":"organization","name":"Avalo Therapeutics, Inc.","symbol":"AVTX"},"owners":[{"id":32667,"kind":"person","name":"Jain Rita","position":1,"cik":"0001707797","reported_name":"Jain Rita","relationship":{"director":true,"officer":false,"ten_percent_owner":false,"other":false}}],"security":"Stock Option (Right to Buy)","published_at":"2026-07-02T20:05:24.000Z","date":"2026-06-30","kind":"grant","planned":false,"acquired":true,"shares":1080,"price":15.04,"value":16243.2,"ownership":{"direct":true},"footnotes":[{"field":"derivative.exercise_date","element":"exerciseDate","label":"F1","text":"The options were granted on June 30, 2026, and are 100% vested."}],"balance_after":1080,"derivative":{"exercise_price":18.48,"expiration_date":"2036-06-30","underlying":"Common Stock","underlying_shares":1080},"source":{"system":"sec-edgar","filing":"0001707797-26-000014","document":"form4-07022026_040717.xml","document_sequence":1,"table":"derivative","row_type":"transaction","position":1,"url":"https://www.sec.gov/Archives/edgar/data/1534120/000170779726000014/form4-07022026_040717.xml","form_type":"4"}},{"id":726215,"issuer":{"id":4936,"kind":"organization","name":"Avalo Therapeutics, Inc.","symbol":"AVTX"},"owners":[{"id":17865,"kind":"person","name":"Doyle Mittie","position":1,"cik":"0001918845","reported_name":"Doyle Mittie","relationship":{"director":false,"officer":true,"ten_percent_owner":false,"other":false,"officer_title":"Chief Medical Officer"}}],"security":"Stock Option (Right to Buy)","published_at":"2026-06-25T21:24:52.000Z","date":"2026-06-23","kind":"exercise","planned":true,"acquired":false,"shares":1450,"price":0,"value":0.0,"ownership":{"direct":true},"footnotes":[{"field":"kind","element":"transactionCoding","label":"F1","text":"The transactions reported in this Form 4 were effected pursuant to a Rule 10b5-1 trading plan adopted by the Reporting Person on November 13, 2025."},{"field":"derivative.exercise_date","element":"exerciseDate","label":"F2","text":"The stock option vests twenty-five percent (25%) on January 28, 2026 and the remainder will vest in equal monthly installments over the following three (3) years, subject to the Reporting Person's continued service on each such vesting date."}],"balance_after":116871,"derivative":{"exercise_price":8.04,"expiration_date":"2035-01-28","underlying":"Common Stock","underlying_shares":1450},"source":{"system":"sec-edgar","filing":"0001918845-26-000020","document":"form4-06252026_090648.xml","document_sequence":1,"table":"derivative","row_type":"transaction","position":3,"url":"https://www.sec.gov/Archives/edgar/data/1534120/000191884526000020/form4-06252026_090648.xml","form_type":"4"}},{"id":726214,"issuer":{"id":4936,"kind":"organization","name":"Avalo Therapeutics, Inc.","symbol":"AVTX"},"owners":[{"id":17865,"kind":"person","name":"Doyle Mittie","position":1,"cik":"0001918845","reported_name":"Doyle Mittie","relationship":{"director":false,"officer":true,"ten_percent_owner":false,"other":false,"officer_title":"Chief Medical Officer"}}],"security":"Common Stock","published_at":"2026-06-25T21:24:52.000Z","date":"2026-06-23","kind":"sale","planned":true,"acquired":false,"shares":1450,"price":18,"value":26100.0,"ownership":{"direct":true},"footnotes":[{"field":"kind","element":"transactionCoding","label":"F1","text":"The transactions reported in this Form 4 were effected pursuant to a Rule 10b5-1 trading plan adopted by the Reporting Person on November 13, 2025."}],"balance_after":51776,"source":{"system":"sec-edgar","filing":"0001918845-26-000020","document":"form4-06252026_090648.xml","document_sequence":1,"table":"nonDerivative","row_type":"transaction","position":2,"url":"https://www.sec.gov/Archives/edgar/data/1534120/000191884526000020/form4-06252026_090648.xml","form_type":"4"}},{"id":726213,"issuer":{"id":4936,"kind":"organization","name":"Avalo Therapeutics, Inc.","symbol":"AVTX"},"owners":[{"id":17865,"kind":"person","name":"Doyle Mittie","position":1,"cik":"0001918845","reported_name":"Doyle Mittie","relationship":{"director":false,"officer":true,"ten_percent_owner":false,"other":false,"officer_title":"Chief Medical Officer"}}],"security":"Common Stock","published_at":"2026-06-25T21:24:52.000Z","date":"2026-06-23","kind":"exercise","planned":true,"acquired":true,"shares":1450,"price":8.04,"value":11658.0,"ownership":{"direct":true},"footnotes":[{"field":"kind","element":"transactionCoding","label":"F1","text":"The transactions reported in this Form 4 were effected pursuant to a Rule 10b5-1 trading plan adopted by the Reporting Person on November 13, 2025."}],"balance_after":53226,"source":{"system":"sec-edgar","filing":"0001918845-26-000020","document":"form4-06252026_090648.xml","document_sequence":1,"table":"nonDerivative","row_type":"transaction","position":1,"url":"https://www.sec.gov/Archives/edgar/data/1534120/000191884526000020/form4-06252026_090648.xml","form_type":"4"}},{"id":726709,"issuer":{"id":4936,"kind":"organization","name":"Avalo Therapeutics, Inc.","symbol":"AVTX"},"owners":[{"id":33068,"kind":"person","name":"Philip Ron M","position":1,"cik":"0002063957","reported_name":"Philip Ron M","relationship":{"director":true,"officer":false,"ten_percent_owner":false,"other":false}}],"security":"Stock Option (Right to Buy)","published_at":"2026-06-25T21:24:24.000Z","date":"2026-06-23","kind":"grant","planned":false,"acquired":true,"shares":40200,"price":0,"value":0.0,"ownership":{"direct":true},"footnotes":[{"field":"derivative.exercise_date","element":"exerciseDate","label":"F1","text":"The stock option vests in three substantially equal annual installments on the first, second and third anniversary of the date of grant, subject to the Eligible Director's continued service on each such vesting date."}],"balance_after":40200,"derivative":{"exercise_price":17.83,"expiration_date":"2036-06-23","underlying":"Common Stock","underlying_shares":40200},"source":{"system":"sec-edgar","filing":"0002063957-26-000005","document":"form4-06252026_090620.xml","document_sequence":1,"table":"derivative","row_type":"transaction","position":1,"url":"https://www.sec.gov/Archives/edgar/data/2063957/000206395726000005/form4-06252026_090620.xml","form_type":"4"}},{"id":740295,"issuer":{"id":4936,"kind":"organization","name":"Avalo Therapeutics, Inc.","symbol":"AVTX"},"owners":[{"id":24237,"kind":"person","name":"Riley Jennifer","position":1,"cik":"0002047607","reported_name":"Riley Jennifer","relationship":{"director":false,"officer":true,"ten_percent_owner":false,"other":false,"officer_title":"Chief Strategy Officer"}}],"security":"Common Stock","published_at":"2026-06-12T20:43:18.000Z","date":"2026-06-10","kind":"tax_withholding","planned":false,"acquired":false,"shares":588,"price":13.1,"value":7702.8,"ownership":{"direct":true},"footnotes":[{"field":"balance_after","element":"sharesOwnedFollowingTransaction","label":"F1","text":"Includes 3,429 shares acquired pursuant to the Issuer's Employee Stock Purchase Plan as a part of this reporting transaction."}],"balance_after":39696,"source":{"system":"sec-edgar","filing":"0002047607-26-000006","document":"form4-06122026_080614.xml","document_sequence":1,"table":"nonDerivative","row_type":"transaction","position":1,"url":"https://www.sec.gov/Archives/edgar/data/2047607/000204760726000006/form4-06122026_080614.xml","form_type":"4"}},{"id":739267,"issuer":{"id":4936,"kind":"organization","name":"Avalo Therapeutics, Inc.","symbol":"AVTX"},"owners":[{"id":38585,"kind":"person","name":"VARKI PAUL","position":1,"cik":"0001677896","reported_name":"VARKI PAUL","relationship":{"director":false,"officer":true,"ten_percent_owner":false,"other":false,"officer_title":"Chief Legal Officer"}}],"security":"Common Stock","published_at":"2026-06-12T20:41:22.000Z","date":"2026-06-10","kind":"tax_withholding","planned":false,"acquired":false,"shares":1081,"price":13.1,"value":14161.1,"ownership":{"direct":true},"footnotes":[{"field":"balance_after","element":"sharesOwnedFollowingTransaction","label":"F1","text":"Includes 5,723 shares acquired pursuant to the Issuer's Employee Stock Purchase Plan as a part of this reporting transaction."}],"balance_after":32576,"source":{"system":"sec-edgar","filing":"0001677896-26-000008","document":"form4-06122026_080618.xml","document_sequence":1,"table":"nonDerivative","row_type":"transaction","position":1,"url":"https://www.sec.gov/Archives/edgar/data/1534120/000167789626000008/form4-06122026_080618.xml","form_type":"4"}},{"id":740054,"issuer":{"id":4936,"kind":"organization","name":"Avalo Therapeutics, Inc.","symbol":"AVTX"},"owners":[{"id":21663,"kind":"person","name":"Sullivan Christopher Ryan","position":1,"cik":"0001810417","reported_name":"Sullivan Christopher Ryan","relationship":{"director":false,"officer":true,"ten_percent_owner":false,"other":false,"officer_title":"Chief Financial Officer"}}],"security":"Common Stock","published_at":"2026-06-12T20:36:45.000Z","date":"2026-06-10","kind":"tax_withholding","planned":false,"acquired":false,"shares":138,"price":13.1,"value":1807.8,"ownership":{"direct":true},"footnotes":[{"field":"balance_after","element":"sharesOwnedFollowingTransaction","label":"F1","text":"Includes 588 shares acquired pursuant to the Issuer's Employee Stock Purchase Plan as a part of this reporting transaction."}],"balance_after":40773,"source":{"system":"sec-edgar","filing":"0001810417-26-000016","document":"form4-06122026_080641.xml","document_sequence":1,"table":"nonDerivative","row_type":"transaction","position":1,"url":"https://www.sec.gov/Archives/edgar/data/1810417/000181041726000016/form4-06122026_080641.xml","form_type":"4"}},{"id":739266,"issuer":{"id":4936,"kind":"organization","name":"Avalo Therapeutics, Inc.","symbol":"AVTX"},"owners":[{"id":17865,"kind":"person","name":"Doyle Mittie","position":1,"cik":"0001918845","reported_name":"Doyle Mittie","relationship":{"director":false,"officer":true,"ten_percent_owner":false,"other":false,"officer_title":"Chief Medical Officer"}}],"security":"Common Stock","published_at":"2026-06-12T20:26:49.000Z","date":"2026-06-10","kind":"tax_withholding","planned":false,"acquired":false,"shares":1084,"price":13.1,"value":14200.4,"ownership":{"direct":true},"footnotes":[{"field":"balance_after","element":"sharesOwnedFollowingTransaction","label":"F1","text":"Includes 5,738 shares acquired pursuant to the Issuer's Employee Stock Purchase Plan as a part of this reporting transaction."}],"balance_after":51776,"source":{"system":"sec-edgar","filing":"0001918845-26-000018","document":"form4-06122026_080645.xml","document_sequence":1,"table":"nonDerivative","row_type":"transaction","position":1,"url":"https://www.sec.gov/Archives/edgar/data/1534120/000191884526000018/form4-06122026_080645.xml","form_type":"4"}},{"id":749268,"issuer":{"id":4936,"kind":"organization","name":"Avalo Therapeutics, Inc.","symbol":"AVTX"},"owners":[{"id":27193,"kind":"person","name":"Lind Kevin Robert","position":1,"cik":"0001677036","reported_name":"Lind Kevin Robert","relationship":{"director":true,"officer":false,"ten_percent_owner":false,"other":false}}],"security":"Stock Option (Right to Buy)","published_at":"2026-06-04T20:10:15.000Z","date":"2026-06-02","kind":"grant","planned":false,"acquired":true,"shares":20100,"price":0,"value":0.0,"ownership":{"direct":true},"footnotes":[{"field":"derivative.exercise_date","element":"exerciseDate","label":"F1","text":"The stock option vests 100% on the first anniversary of the date of grant, subject to the director's continued service on such vesting date."}],"balance_after":20100,"derivative":{"exercise_price":13.96,"expiration_date":"2036-06-02","underlying":"Common Stock","underlying_shares":20100},"source":{"system":"sec-edgar","filing":"0001677036-26-000004","document":"form4-06042026_040609.xml","document_sequence":1,"table":"derivative","row_type":"transaction","position":1,"url":"https://www.sec.gov/Archives/edgar/data/1534120/000167703626000004/form4-06042026_040609.xml","form_type":"4"}},{"id":749884,"issuer":{"id":4936,"kind":"organization","name":"Avalo Therapeutics, Inc.","symbol":"AVTX"},"owners":[{"id":41414,"kind":"person","name":"Truex Samantha","position":1,"cik":"0002017156","reported_name":"Truex Samantha","relationship":{"director":true,"officer":false,"ten_percent_owner":false,"other":false}}],"security":"Stock Option (Right to Buy)","published_at":"2026-06-04T20:10:14.000Z","date":"2026-06-02","kind":"grant","planned":false,"acquired":true,"shares":20100,"price":0,"value":0.0,"ownership":{"direct":true},"footnotes":[{"field":"derivative.exercise_date","element":"exerciseDate","label":"F1","text":"The stock option vests 100% on the first anniversary of the date of grant, subject to the director's continued service on such vesting date."}],"balance_after":20100,"derivative":{"exercise_price":13.96,"expiration_date":"2036-06-02","underlying":"Common Stock","underlying_shares":20100},"source":{"system":"sec-edgar","filing":"0002017156-26-000004","document":"form4-06042026_040611.xml","document_sequence":1,"table":"derivative","row_type":"transaction","position":1,"url":"https://www.sec.gov/Archives/edgar/data/2017156/000201715626000004/form4-06042026_040611.xml","form_type":"4"}},{"id":749405,"issuer":{"id":4936,"kind":"organization","name":"Avalo Therapeutics, Inc.","symbol":"AVTX"},"owners":[{"id":41289,"kind":"person","name":"KAPLAN GILLA","position":1,"cik":"0001247024","reported_name":"KAPLAN GILLA","relationship":{"director":true,"officer":false,"ten_percent_owner":false,"other":false}}],"security":"Stock Option (Right to Buy)","published_at":"2026-06-04T20:10:13.000Z","date":"2026-06-02","kind":"grant","planned":false,"acquired":true,"shares":20100,"price":0,"value":0.0,"ownership":{"direct":true},"footnotes":[{"field":"derivative.exercise_date","element":"exerciseDate","label":"F1","text":"The stock option vests 100% on the first anniversary of the date of grant, subject to the director's continued service on such vesting date."}],"balance_after":20100,"derivative":{"exercise_price":13.96,"expiration_date":"2036-06-02","underlying":"Common Stock","underlying_shares":20100},"source":{"system":"sec-edgar","filing":"0001247024-26-000004","document":"form4-06042026_040607.xml","document_sequence":1,"table":"derivative","row_type":"transaction","position":1,"url":"https://www.sec.gov/Archives/edgar/data/1247024/000124702426000004/form4-06042026_040607.xml","form_type":"4"}},{"id":749763,"issuer":{"id":4936,"kind":"organization","name":"Avalo Therapeutics, Inc.","symbol":"AVTX"},"owners":[{"id":41382,"kind":"person","name":"KANTOFF AARON","position":1,"cik":"0001862734","reported_name":"KANTOFF AARON","relationship":{"director":true,"officer":false,"ten_percent_owner":false,"other":false}}],"security":"Stock Option (Right to Buy)","published_at":"2026-06-04T20:10:12.000Z","date":"2026-06-02","kind":"grant","planned":false,"acquired":true,"shares":20100,"price":0,"value":0.0,"ownership":{"direct":true},"footnotes":[{"field":"derivative.exercise_date","element":"exerciseDate","label":"F1","text":"The stock option vests 100% on the first anniversary of the date of grant, subject to the director's continued service on such vesting date."}],"balance_after":20100,"derivative":{"exercise_price":13.96,"expiration_date":"2036-06-02","underlying":"Common Stock","underlying_shares":20100},"source":{"system":"sec-edgar","filing":"0001862734-26-000004","document":"form4-06042026_040605.xml","document_sequence":1,"table":"derivative","row_type":"transaction","position":1,"url":"https://www.sec.gov/Archives/edgar/data/1862734/000186273426000004/form4-06042026_040605.xml","form_type":"4"}},{"id":749485,"issuer":{"id":4936,"kind":"organization","name":"Avalo Therapeutics, Inc.","symbol":"AVTX"},"owners":[{"id":37240,"kind":"person","name":"Heffernan Michael Thomas","position":1,"cik":"0001448914","reported_name":"Heffernan Michael Thomas","relationship":{"director":true,"officer":false,"ten_percent_owner":false,"other":false}}],"security":"Stock Option (Right to Buy)","published_at":"2026-06-04T20:10:10.000Z","date":"2026-06-02","kind":"grant","planned":false,"acquired":true,"shares":29500,"price":0,"value":0.0,"ownership":{"direct":true},"footnotes":[{"field":"derivative.exercise_date","element":"exerciseDate","label":"F1","text":"The stock option vests 100% on the first anniversary of the date of grant, subject to the director's continued service on such vesting date."}],"balance_after":29500,"derivative":{"exercise_price":13.96,"expiration_date":"2036-06-02","underlying":"Common Stock","underlying_shares":29500},"source":{"system":"sec-edgar","filing":"0001448914-26-000004","document":"form4-06042026_040603.xml","document_sequence":1,"table":"derivative","row_type":"transaction","position":1,"url":"https://www.sec.gov/Archives/edgar/data/1448914/000144891426000004/form4-06042026_040603.xml","form_type":"4"}},{"id":749267,"issuer":{"id":4936,"kind":"organization","name":"Avalo Therapeutics, Inc.","symbol":"AVTX"},"owners":[{"id":32667,"kind":"person","name":"Jain Rita","position":1,"cik":"0001707797","reported_name":"Jain Rita","relationship":{"director":true,"officer":false,"ten_percent_owner":false,"other":false}}],"security":"Stock Option (Right to Buy)","published_at":"2026-06-04T20:10:05.000Z","date":"2026-06-02","kind":"grant","planned":false,"acquired":true,"shares":20100,"price":0,"value":0.0,"ownership":{"direct":true},"footnotes":[{"field":"derivative.exercise_date","element":"exerciseDate","label":"F1","text":"The stock option vests 100% on the first anniversary of the date of grant, subject to the director's continued service on such vesting date."}],"balance_after":20100,"derivative":{"exercise_price":13.96,"expiration_date":"2036-06-02","underlying":"Common Stock","underlying_shares":20100},"source":{"system":"sec-edgar","filing":"0001707797-26-000008","document":"form4-06042026_040601.xml","document_sequence":1,"table":"derivative","row_type":"transaction","position":1,"url":"https://www.sec.gov/Archives/edgar/data/1534120/000170779726000008/form4-06042026_040601.xml","form_type":"4"}},{"id":756754,"issuer":{"id":4936,"kind":"organization","name":"Avalo Therapeutics, Inc.","symbol":"AVTX"},"owners":[{"id":17865,"kind":"person","name":"Doyle Mittie","position":1,"cik":"0001918845","reported_name":"Doyle Mittie","relationship":{"director":false,"officer":true,"ten_percent_owner":false,"other":false,"officer_title":"Chief Medical Officer"}}],"security":"Stock Option (Right to Buy)","published_at":"2026-06-01T20:05:22.000Z","date":"2026-05-28","kind":"exercise","planned":true,"acquired":false,"shares":679,"price":0,"value":0.0,"ownership":{"direct":true},"footnotes":[{"field":"kind","element":"transactionCoding","label":"F1","text":"The transactions reported in this Form 4 were effected pursuant to a Rule 10b5-1 trading plan adopted by the Reporting Person on November 13, 2025."},{"field":"derivative.exercise_date","element":"exerciseDate","label":"F2","text":"The stock option vests twenty-five percent (25%) on January 28, 2026 and the remainder will vest in equal monthly installments over the following three (3) years, subject to the Reporting Person's continued service on each such vesting date."}],"balance_after":118321,"derivative":{"exercise_price":8.04,"expiration_date":"2035-01-28","underlying":"Common Stock","underlying_shares":679},"source":{"system":"sec-edgar","filing":"0001918845-26-000016","document":"form4-06012026_040618.xml","document_sequence":1,"table":"derivative","row_type":"transaction","position":3,"url":"https://www.sec.gov/Archives/edgar/data/1534120/000191884526000016/form4-06012026_040618.xml","form_type":"4"}},{"id":756753,"issuer":{"id":4936,"kind":"organization","name":"Avalo Therapeutics, Inc.","symbol":"AVTX"},"owners":[{"id":17865,"kind":"person","name":"Doyle Mittie","position":1,"cik":"0001918845","reported_name":"Doyle Mittie","relationship":{"director":false,"officer":true,"ten_percent_owner":false,"other":false,"officer_title":"Chief Medical Officer"}}],"security":"Common Stock","published_at":"2026-06-01T20:05:22.000Z","date":"2026-05-28","kind":"sale","planned":true,"acquired":false,"shares":679,"price":16,"value":10864.0,"ownership":{"direct":true},"footnotes":[{"field":"kind","element":"transactionCoding","label":"F1","text":"The transactions reported in this Form 4 were effected pursuant to a Rule 10b5-1 trading plan adopted by the Reporting Person on November 13, 2025."}],"balance_after":47122,"source":{"system":"sec-edgar","filing":"0001918845-26-000016","document":"form4-06012026_040618.xml","document_sequence":1,"table":"nonDerivative","row_type":"transaction","position":2,"url":"https://www.sec.gov/Archives/edgar/data/1534120/000191884526000016/form4-06012026_040618.xml","form_type":"4"}},{"id":756752,"issuer":{"id":4936,"kind":"organization","name":"Avalo Therapeutics, Inc.","symbol":"AVTX"},"owners":[{"id":17865,"kind":"person","name":"Doyle Mittie","position":1,"cik":"0001918845","reported_name":"Doyle Mittie","relationship":{"director":false,"officer":true,"ten_percent_owner":false,"other":false,"officer_title":"Chief Medical Officer"}}],"security":"Common Stock","published_at":"2026-06-01T20:05:22.000Z","date":"2026-05-28","kind":"exercise","planned":true,"acquired":true,"shares":679,"price":8.04,"value":5459.16,"ownership":{"direct":true},"footnotes":[{"field":"kind","element":"transactionCoding","label":"F1","text":"The transactions reported in this Form 4 were effected pursuant to a Rule 10b5-1 trading plan adopted by the Reporting Person on November 13, 2025."}],"balance_after":47801,"source":{"system":"sec-edgar","filing":"0001918845-26-000016","document":"form4-06012026_040618.xml","document_sequence":1,"table":"nonDerivative","row_type":"transaction","position":1,"url":"https://www.sec.gov/Archives/edgar/data/1534120/000191884526000016/form4-06012026_040618.xml","form_type":"4"}},{"id":764131,"issuer":{"id":4936,"kind":"organization","name":"Avalo Therapeutics, Inc.","symbol":"AVTX"},"owners":[{"id":24237,"kind":"person","name":"Riley Jennifer","position":1,"cik":"0002047607","reported_name":"Riley Jennifer","relationship":{"director":false,"officer":true,"ten_percent_owner":false,"other":false,"officer_title":"Chief Strategy Officer"}}],"security":"Common Stock","published_at":"2026-05-26T20:10:15.000Z","date":"2026-05-21","kind":"grant","planned":false,"acquired":true,"shares":34200,"price":0,"value":0.0,"ownership":{"direct":true},"footnotes":[{"field":"kind","element":"transactionCoding","label":"F1","text":"Represents performance stock units (\"PSUs\") granted to the Reporting Person on August 19, 2025. Each PSU represents a contingent right to receive one share of the Issuer's Common Stock upon the achievement of certain performance goals. On May 21, 2026, the Compensation Committee of the Issuer certified achievement of such performance goals. As a result, the shares subject to the PSUs shall fully vest on August 19, 2028, subject to the Reporting Person's continued service on such vesting date."}],"balance_after":36855,"source":{"system":"sec-edgar","filing":"0002047607-26-000004","document":"form4-05262026_040508.xml","document_sequence":1,"table":"nonDerivative","row_type":"transaction","position":1,"url":"https://www.sec.gov/Archives/edgar/data/2047607/000204760726000004/form4-05262026_040508.xml","form_type":"4"}},{"id":763904,"issuer":{"id":4936,"kind":"organization","name":"Avalo Therapeutics, Inc.","symbol":"AVTX"},"owners":[{"id":21663,"kind":"person","name":"Sullivan Christopher Ryan","position":1,"cik":"0001810417","reported_name":"Sullivan Christopher Ryan","relationship":{"director":false,"officer":true,"ten_percent_owner":false,"other":false,"officer_title":"Chief Financial Officer"}}],"security":"Common Stock","published_at":"2026-05-26T20:10:13.000Z","date":"2026-05-21","kind":"grant","planned":false,"acquired":true,"shares":39900,"price":0,"value":0.0,"ownership":{"direct":true},"footnotes":[{"field":"kind","element":"transactionCoding","label":"F1","text":"Represents performance stock units (\"PSUs\") granted to the Reporting Person on August 19, 2025. Each PSU represents a contingent right to receive one share of the Issuer's Common Stock upon the achievement of certain performance goals. On May 21, 2026, the Compensation Committee of the Issuer certified achievement of such performance goals. As a result, the shares subject to the PSUs shall fully vest on August 19, 2028, subject to the Reporting Person's continued service on such vesting date."}],"balance_after":40323,"source":{"system":"sec-edgar","filing":"0001810417-26-000014","document":"form4-05262026_040507.xml","document_sequence":1,"table":"nonDerivative","row_type":"transaction","position":1,"url":"https://www.sec.gov/Archives/edgar/data/1810417/000181041726000014/form4-05262026_040507.xml","form_type":"4"}},{"id":763304,"issuer":{"id":4936,"kind":"organization","name":"Avalo Therapeutics, Inc.","symbol":"AVTX"},"owners":[{"id":38585,"kind":"person","name":"VARKI PAUL","position":1,"cik":"0001677896","reported_name":"VARKI PAUL","relationship":{"director":false,"officer":true,"ten_percent_owner":false,"other":false,"officer_title":"Chief Legal Officer"}}],"security":"Common Stock","published_at":"2026-05-26T20:10:11.000Z","date":"2026-05-21","kind":"grant","planned":false,"acquired":true,"shares":24300,"price":0,"value":0.0,"ownership":{"direct":true},"footnotes":[{"field":"kind","element":"transactionCoding","label":"F1","text":"Represents performance stock units (\"PSUs\") granted to the Reporting Person on August 19, 2025. Each PSU represents a contingent right to receive one share of the Issuer's Common Stock upon the achievement of certain performance goals. On May 21, 2026, the Compensation Committee of the Issuer certified achievement of such performance goals. As a result, the shares subject to the PSUs shall fully vest on August 19, 2028, subject to the Reporting Person's continued service on such vesting date."}],"balance_after":27934,"source":{"system":"sec-edgar","filing":"0001677896-26-000006","document":"form4-05262026_040505.xml","document_sequence":1,"table":"nonDerivative","row_type":"transaction","position":1,"url":"https://www.sec.gov/Archives/edgar/data/1534120/000167789626000006/form4-05262026_040505.xml","form_type":"4"}},{"id":763303,"issuer":{"id":4936,"kind":"organization","name":"Avalo Therapeutics, Inc.","symbol":"AVTX"},"owners":[{"id":17865,"kind":"person","name":"Doyle Mittie","position":1,"cik":"0001918845","reported_name":"Doyle Mittie","relationship":{"director":false,"officer":true,"ten_percent_owner":false,"other":false,"officer_title":"Chief Medical Officer"}}],"security":"Common Stock","published_at":"2026-05-26T20:10:10.000Z","date":"2026-05-21","kind":"grant","planned":false,"acquired":true,"shares":43500,"price":0,"value":0.0,"ownership":{"direct":true},"footnotes":[{"field":"kind","element":"transactionCoding","label":"F1","text":"Represents performance stock units (\"PSUs\") granted to the Reporting Person on August 19, 2025. Each PSU represents a contingent right to receive one share of the Issuer's Common Stock upon the achievement of certain performance goals. On May 21, 2026, the Compensation Committee of the Issuer certified achievement of such performance goals. As a result, the shares subject to the PSUs shall fully vest on August 19, 2028, subject to the Reporting Person's continued service on such vesting date."}],"balance_after":47122,"source":{"system":"sec-edgar","filing":"0001918845-26-000014","document":"form4-05262026_040503.xml","document_sequence":1,"table":"nonDerivative","row_type":"transaction","position":1,"url":"https://www.sec.gov/Archives/edgar/data/1534120/000191884526000014/form4-05262026_040503.xml","form_type":"4"}},{"id":763302,"issuer":{"id":4936,"kind":"organization","name":"Avalo Therapeutics, Inc.","symbol":"AVTX"},"owners":[{"id":35024,"kind":"person","name":"NEIL GARRY ARTHUR","position":1,"cik":"0001586785","reported_name":"NEIL GARRY ARTHUR","relationship":{"director":true,"officer":true,"ten_percent_owner":false,"other":false,"officer_title":"Chief Executive Officer"}}],"security":"Common Stock","published_at":"2026-05-26T20:10:07.000Z","date":"2026-05-21","kind":"grant","planned":false,"acquired":true,"shares":100200,"price":0,"value":0.0,"ownership":{"direct":true},"footnotes":[{"field":"kind","element":"transactionCoding","label":"F1","text":"Represents performance stock units (\"PSUs\") granted to the Reporting Person on August 19, 2025. Each PSU represents a contingent right to receive one share of the Issuer's Common Stock upon the achievement of certain performance goals. On May 21, 2026, the Compensation Committee of the Issuer certified achievement of such performance goals. As a result, the shares subject to the PSUs shall fully vest on August 19, 2028, subject to the Reporting Person's continued service on such vesting date."}],"balance_after":190314,"source":{"system":"sec-edgar","filing":"0001586785-26-000006","document":"form4-05262026_040501.xml","document_sequence":1,"table":"nonDerivative","row_type":"transaction","position":1,"url":"https://www.sec.gov/Archives/edgar/data/1534120/000158678526000006/form4-05262026_040501.xml","form_type":"4"}},{"id":771355,"issuer":{"id":4936,"kind":"organization","name":"Avalo Therapeutics, Inc.","symbol":"AVTX"},"owners":[{"id":17865,"kind":"person","name":"Doyle Mittie","position":1,"cik":"0001918845","reported_name":"Doyle Mittie","relationship":{"director":false,"officer":true,"ten_percent_owner":false,"other":false,"officer_title":"Chief Medical Officer"}}],"security":"Stock Option (Right to Buy)","published_at":"2026-05-19T20:10:08.000Z","date":"2026-05-15","kind":"exercise","planned":true,"acquired":false,"shares":3000,"price":0,"value":0.0,"ownership":{"direct":true},"footnotes":[{"field":"kind","element":"transactionCoding","label":"F1","text":"The transactions reported in this Form 4 were effected pursuant to a Rule 10b5-1 trading plan adopted by the Reporting Person on November 13, 2025."},{"field":"derivative.exercise_date","element":"exerciseDate","label":"F2","text":"The stock option vests twenty-five percent (25%) on July 15, 2025 and the remainder will vest in equal monthly installments over the following three (3) years, subject to the Reporting Person's continued service on each such vesting date."}],"balance_after":128625,"derivative":{"exercise_price":12.65,"expiration_date":"2034-07-15","underlying":"Common Stock","underlying_shares":3000},"source":{"system":"sec-edgar","filing":"0001918845-26-000012","document":"form4-05192026_040503.xml","document_sequence":1,"table":"derivative","row_type":"transaction","position":3,"url":"https://www.sec.gov/Archives/edgar/data/1534120/000191884526000012/form4-05192026_040503.xml","form_type":"4"}},{"id":771354,"issuer":{"id":4936,"kind":"organization","name":"Avalo Therapeutics, Inc.","symbol":"AVTX"},"owners":[{"id":17865,"kind":"person","name":"Doyle Mittie","position":1,"cik":"0001918845","reported_name":"Doyle Mittie","relationship":{"director":false,"officer":true,"ten_percent_owner":false,"other":false,"officer_title":"Chief Medical Officer"}}],"security":"Common Stock","published_at":"2026-05-19T20:10:08.000Z","date":"2026-05-15","kind":"sale","planned":true,"acquired":false,"shares":3000,"price":18.76,"value":56280.0,"ownership":{"direct":true},"footnotes":[{"field":"kind","element":"transactionCoding","label":"F1","text":"The transactions reported in this Form 4 were effected pursuant to a Rule 10b5-1 trading plan adopted by the Reporting Person on November 13, 2025."}],"balance_after":3622,"source":{"system":"sec-edgar","filing":"0001918845-26-000012","document":"form4-05192026_040503.xml","document_sequence":1,"table":"nonDerivative","row_type":"transaction","position":2,"url":"https://www.sec.gov/Archives/edgar/data/1534120/000191884526000012/form4-05192026_040503.xml","form_type":"4"}},{"id":771353,"issuer":{"id":4936,"kind":"organization","name":"Avalo Therapeutics, Inc.","symbol":"AVTX"},"owners":[{"id":17865,"kind":"person","name":"Doyle Mittie","position":1,"cik":"0001918845","reported_name":"Doyle Mittie","relationship":{"director":false,"officer":true,"ten_percent_owner":false,"other":false,"officer_title":"Chief Medical Officer"}}],"security":"Common Stock","published_at":"2026-05-19T20:10:08.000Z","date":"2026-05-15","kind":"exercise","planned":true,"acquired":true,"shares":3000,"price":12.65,"value":37950.0,"ownership":{"direct":true},"footnotes":[{"field":"kind","element":"transactionCoding","label":"F1","text":"The transactions reported in this Form 4 were effected pursuant to a Rule 10b5-1 trading plan adopted by the Reporting Person on November 13, 2025."}],"balance_after":6622,"source":{"system":"sec-edgar","filing":"0001918845-26-000012","document":"form4-05192026_040503.xml","document_sequence":1,"table":"nonDerivative","row_type":"transaction","position":1,"url":"https://www.sec.gov/Archives/edgar/data/1534120/000191884526000012/form4-05192026_040503.xml","form_type":"4"}},{"id":784822,"issuer":{"id":4936,"kind":"organization","name":"Avalo Therapeutics, Inc.","symbol":"AVTX"},"owners":[{"id":21663,"kind":"person","name":"Sullivan Christopher Ryan","position":1,"cik":"0001810417","reported_name":"Sullivan Christopher Ryan","relationship":{"director":false,"officer":true,"ten_percent_owner":false,"other":false,"officer_title":"Chief Financial Officer"}}],"security":"Stock Option (Right to Buy)","published_at":"2026-05-11T20:05:09.000Z","date":"2026-05-07","kind":"exercise","planned":true,"acquired":false,"shares":18606,"price":0,"value":0.0,"ownership":{"direct":true},"footnotes":[{"field":"kind","element":"transactionCoding","label":"F1","text":"The transactions reported in this Form 4 were effected pursuant to a Rule 10b5-1 trading plan adopted by the Reporting Person on November 12, 2025."},{"field":"derivative.exercise_date","element":"exerciseDate","label":"F3","text":"The stock option vests 25% on March 28, 2025, and 1/36 monthly thereafter, subject to the Reporting Person's continued service on such vesting date."}],"balance_after":168094,"derivative":{"exercise_price":9.88,"expiration_date":"2034-08-13","underlying":"Common Stock","underlying_shares":18606},"source":{"system":"sec-edgar","filing":"0001810417-26-000012","document":"form4-05112026_040503.xml","document_sequence":1,"table":"derivative","row_type":"transaction","position":3,"url":"https://www.sec.gov/Archives/edgar/data/1810417/000181041726000012/form4-05112026_040503.xml","form_type":"4"}},{"id":784821,"issuer":{"id":4936,"kind":"organization","name":"Avalo Therapeutics, Inc.","symbol":"AVTX"},"owners":[{"id":21663,"kind":"person","name":"Sullivan Christopher Ryan","position":1,"cik":"0001810417","reported_name":"Sullivan Christopher Ryan","relationship":{"director":false,"officer":true,"ten_percent_owner":false,"other":false,"officer_title":"Chief Financial Officer"}}],"security":"Common Stock","published_at":"2026-05-11T20:05:09.000Z","date":"2026-05-07","kind":"sale","planned":true,"acquired":false,"shares":18606,"price":24.1222,"value":448817.6532,"ownership":{"direct":true},"footnotes":[{"field":"kind","element":"transactionCoding","label":"F1","text":"The transactions reported in this Form 4 were effected pursuant to a Rule 10b5-1 trading plan adopted by the Reporting Person on November 12, 2025."},{"field":"price","element":"transactionPricePerShare","label":"F2","text":"The reported securities were sold in multiple transactions at prices ranging from $24.05 to $24.23. The Reporting Person undertakes to provide to the Issuer, any security holder of the Issuer or the staff of the Securities and Exchange Commission, upon request, full information regarding the number of shares sold at each separate price within such range."}],"balance_after":423,"source":{"system":"sec-edgar","filing":"0001810417-26-000012","document":"form4-05112026_040503.xml","document_sequence":1,"table":"nonDerivative","row_type":"transaction","position":2,"url":"https://www.sec.gov/Archives/edgar/data/1810417/000181041726000012/form4-05112026_040503.xml","form_type":"4"}},{"id":784820,"issuer":{"id":4936,"kind":"organization","name":"Avalo Therapeutics, Inc.","symbol":"AVTX"},"owners":[{"id":21663,"kind":"person","name":"Sullivan Christopher Ryan","position":1,"cik":"0001810417","reported_name":"Sullivan Christopher Ryan","relationship":{"director":false,"officer":true,"ten_percent_owner":false,"other":false,"officer_title":"Chief Financial Officer"}}],"security":"Common Stock","published_at":"2026-05-11T20:05:09.000Z","date":"2026-05-07","kind":"exercise","planned":true,"acquired":true,"shares":18606,"price":9.88,"value":183827.28,"ownership":{"direct":true},"footnotes":[{"field":"kind","element":"transactionCoding","label":"F1","text":"The transactions reported in this Form 4 were effected pursuant to a Rule 10b5-1 trading plan adopted by the Reporting Person on November 12, 2025."}],"balance_after":19029,"source":{"system":"sec-edgar","filing":"0001810417-26-000012","document":"form4-05112026_040503.xml","document_sequence":1,"table":"nonDerivative","row_type":"transaction","position":1,"url":"https://www.sec.gov/Archives/edgar/data/1810417/000181041726000012/form4-05112026_040503.xml","form_type":"4"}},{"id":788301,"issuer":{"id":4936,"kind":"organization","name":"Avalo Therapeutics, Inc.","symbol":"AVTX"},"owners":[{"id":38585,"kind":"person","name":"VARKI PAUL","position":1,"cik":"0001677896","reported_name":"VARKI PAUL","relationship":{"director":false,"officer":true,"ten_percent_owner":false,"other":false,"officer_title":"Chief Legal Officer"}}],"security":"Stock Option (Right to Buy)","published_at":"2026-05-07T20:18:26.000Z","date":"2026-05-06","kind":"exercise","planned":true,"acquired":false,"shares":12563,"price":0,"value":0.0,"ownership":{"direct":true},"footnotes":[{"field":"kind","element":"transactionCoding","label":"F1","text":"The transactions reported in this Form 4 were effected pursuant to a Rule 10b5-1 trading plan adopted by the Reporting Person on November 12, 2025."},{"field":"derivative.exercise_date","element":"exerciseDate","label":"F7","text":"The stock option vests twenty-five percent (25%) on January 28, 2026 and the remainder will vest in equal monthly installments over the following three (3) years, subject to the Reporting Person's continued service on such vesting date."}],"balance_after":87437,"derivative":{"exercise_price":8.04,"expiration_date":"2035-01-28","underlying":"Common Stock","underlying_shares":12563},"source":{"system":"sec-edgar","filing":"0001677896-26-000004","document":"form4-05072026_080504.xml","document_sequence":1,"table":"derivative","row_type":"transaction","position":9,"url":"https://www.sec.gov/Archives/edgar/data/1534120/000167789626000004/form4-05072026_080504.xml","form_type":"4"}},{"id":788300,"issuer":{"id":4936,"kind":"organization","name":"Avalo Therapeutics, Inc.","symbol":"AVTX"},"owners":[{"id":38585,"kind":"person","name":"VARKI PAUL","position":1,"cik":"0001677896","reported_name":"VARKI PAUL","relationship":{"director":false,"officer":true,"ten_percent_owner":false,"other":false,"officer_title":"Chief Legal Officer"}}],"security":"Stock Option (Right to Buy)","published_at":"2026-05-07T20:18:26.000Z","date":"2026-05-06","kind":"exercise","planned":true,"acquired":false,"shares":62500,"price":0,"value":0.0,"ownership":{"direct":true},"footnotes":[{"field":"kind","element":"transactionCoding","label":"F1","text":"The transactions reported in this Form 4 were effected pursuant to a Rule 10b5-1 trading plan adopted by the Reporting Person on November 12, 2025."},{"field":"derivative.exercise_date","element":"exerciseDate","label":"F6","text":"Twenty-five percent (25%) of the Option Shares vest on June 24, 2025 and the remainder of the Option Shares will vest in equal monthly installments on the first day of each month thereafter over the following three (3) years, provided that Optionee remains an employee of the Company on each such vesting date."}],"balance_after":87500,"derivative":{"exercise_price":13.43,"expiration_date":"2034-06-24","underlying":"Common Stock","underlying_shares":62500},"source":{"system":"sec-edgar","filing":"0001677896-26-000004","document":"form4-05072026_080504.xml","document_sequence":1,"table":"derivative","row_type":"transaction","position":8,"url":"https://www.sec.gov/Archives/edgar/data/1534120/000167789626000004/form4-05072026_080504.xml","form_type":"4"}},{"id":788299,"issuer":{"id":4936,"kind":"organization","name":"Avalo Therapeutics, Inc.","symbol":"AVTX"},"owners":[{"id":38585,"kind":"person","name":"VARKI PAUL","position":1,"cik":"0001677896","reported_name":"VARKI PAUL","relationship":{"director":false,"officer":true,"ten_percent_owner":false,"other":false,"officer_title":"Chief Legal Officer"}}],"security":"Common Stock","published_at":"2026-05-07T20:18:26.000Z","date":"2026-05-06","kind":"sale","planned":true,"acquired":false,"shares":400,"price":23.71,"value":9484.0,"ownership":{"direct":true},"footnotes":[{"field":"kind","element":"transactionCoding","label":"F1","text":"The transactions reported in this Form 4 were effected pursuant to a Rule 10b5-1 trading plan adopted by the Reporting Person on November 12, 2025."}],"balance_after":3634,"source":{"system":"sec-edgar","filing":"0001677896-26-000004","document":"form4-05072026_080504.xml","document_sequence":1,"table":"nonDerivative","row_type":"transaction","position":7,"url":"https://www.sec.gov/Archives/edgar/data/1534120/000167789626000004/form4-05072026_080504.xml","form_type":"4"}},{"id":788298,"issuer":{"id":4936,"kind":"organization","name":"Avalo Therapeutics, Inc.","symbol":"AVTX"},"owners":[{"id":38585,"kind":"person","name":"VARKI PAUL","position":1,"cik":"0001677896","reported_name":"VARKI PAUL","relationship":{"director":false,"officer":true,"ten_percent_owner":false,"other":false,"officer_title":"Chief Legal Officer"}}],"security":"Common Stock","published_at":"2026-05-07T20:18:26.000Z","date":"2026-05-06","kind":"sale","planned":true,"acquired":false,"shares":9253,"price":22.6985,"value":210029.2205,"ownership":{"direct":true},"footnotes":[{"field":"kind","element":"transactionCoding","label":"F1","text":"The transactions reported in this Form 4 were effected pursuant to a Rule 10b5-1 trading plan adopted by the Reporting Person on November 12, 2025."},{"field":"price","element":"transactionPricePerShare","label":"F5","text":"The reported securities were sold in multiple transactions at prices ranging from $22.15 to $22.88. The Reporting Person undertakes to provide to the Issuer, any security holder of the Issuer or the staff of the Securities and Exchange Commission, upon request, full information regarding the number of shares sold at each separate price within such range."}],"balance_after":4034,"source":{"system":"sec-edgar","filing":"0001677896-26-000004","document":"form4-05072026_080504.xml","document_sequence":1,"table":"nonDerivative","row_type":"transaction","position":6,"url":"https://www.sec.gov/Archives/edgar/data/1534120/000167789626000004/form4-05072026_080504.xml","form_type":"4"}},{"id":788297,"issuer":{"id":4936,"kind":"organization","name":"Avalo Therapeutics, Inc.","symbol":"AVTX"},"owners":[{"id":38585,"kind":"person","name":"VARKI PAUL","position":1,"cik":"0001677896","reported_name":"VARKI PAUL","relationship":{"director":false,"officer":true,"ten_percent_owner":false,"other":false,"officer_title":"Chief Legal Officer"}}],"security":"Common Stock","published_at":"2026-05-07T20:18:26.000Z","date":"2026-05-06","kind":"sale","planned":true,"acquired":false,"shares":22839,"price":21.2155,"value":484540.8045,"ownership":{"direct":true},"footnotes":[{"field":"kind","element":"transactionCoding","label":"F1","text":"The transactions reported in this Form 4 were effected pursuant to a Rule 10b5-1 trading plan adopted by the Reporting Person on November 12, 2025."},{"field":"price","element":"transactionPricePerShare","label":"F4","text":"The reported securities were sold in multiple transactions at prices ranging from $20.75 to $21.69. The Reporting Person undertakes to provide to the Issuer, any security holder of the Issuer or the staff of the Securities and Exchange Commission, upon request, full information regarding the number of shares sold at each separate price within such range."}],"balance_after":13287,"source":{"system":"sec-edgar","filing":"0001677896-26-000004","document":"form4-05072026_080504.xml","document_sequence":1,"table":"nonDerivative","row_type":"transaction","position":5,"url":"https://www.sec.gov/Archives/edgar/data/1534120/000167789626000004/form4-05072026_080504.xml","form_type":"4"}},{"id":788296,"issuer":{"id":4936,"kind":"organization","name":"Avalo Therapeutics, Inc.","symbol":"AVTX"},"owners":[{"id":38585,"kind":"person","name":"VARKI PAUL","position":1,"cik":"0001677896","reported_name":"VARKI PAUL","relationship":{"director":false,"officer":true,"ten_percent_owner":false,"other":false,"officer_title":"Chief Legal Officer"}}],"security":"Common Stock","published_at":"2026-05-07T20:18:26.000Z","date":"2026-05-06","kind":"sale","planned":true,"acquired":false,"shares":5196,"price":19.7812,"value":102783.1152,"ownership":{"direct":true},"footnotes":[{"field":"kind","element":"transactionCoding","label":"F1","text":"The transactions reported in this Form 4 were effected pursuant to a Rule 10b5-1 trading plan adopted by the Reporting Person on November 12, 2025."},{"field":"price","element":"transactionPricePerShare","label":"F3","text":"The reported securities were sold in multiple transactions at prices ranging from $19.50 to $19.99. The Reporting Person undertakes to provide to the Issuer, any security holder of the Issuer or the staff of the Securities and Exchange Commission, upon request, full information regarding the number of shares sold at each separate price within such range."}],"balance_after":36126,"source":{"system":"sec-edgar","filing":"0001677896-26-000004","document":"form4-05072026_080504.xml","document_sequence":1,"table":"nonDerivative","row_type":"transaction","position":4,"url":"https://www.sec.gov/Archives/edgar/data/1534120/000167789626000004/form4-05072026_080504.xml","form_type":"4"}},{"id":788295,"issuer":{"id":4936,"kind":"organization","name":"Avalo Therapeutics, Inc.","symbol":"AVTX"},"owners":[{"id":38585,"kind":"person","name":"VARKI PAUL","position":1,"cik":"0001677896","reported_name":"VARKI PAUL","relationship":{"director":false,"officer":true,"ten_percent_owner":false,"other":false,"officer_title":"Chief Legal Officer"}}],"security":"Common Stock","published_at":"2026-05-07T20:18:26.000Z","date":"2026-05-06","kind":"sale","planned":true,"acquired":false,"shares":37375,"price":18.912,"value":706836.0,"ownership":{"direct":true},"footnotes":[{"field":"kind","element":"transactionCoding","label":"F1","text":"The transactions reported in this Form 4 were effected pursuant to a Rule 10b5-1 trading plan adopted by the Reporting Person on November 12, 2025."},{"field":"price","element":"transactionPricePerShare","label":"F2","text":"The reported securities were sold in multiple transactions at prices ranging from $18.50 to $19.495. The Reporting Person undertakes to provide to the Issuer, any security holder of the Issuer or the staff of the Securities and Exchange Commission, upon request, full information regarding the number of shares sold at each separate price within such range."}],"balance_after":41322,"source":{"system":"sec-edgar","filing":"0001677896-26-000004","document":"form4-05072026_080504.xml","document_sequence":1,"table":"nonDerivative","row_type":"transaction","position":3,"url":"https://www.sec.gov/Archives/edgar/data/1534120/000167789626000004/form4-05072026_080504.xml","form_type":"4"}},{"id":788294,"issuer":{"id":4936,"kind":"organization","name":"Avalo Therapeutics, Inc.","symbol":"AVTX"},"owners":[{"id":38585,"kind":"person","name":"VARKI PAUL","position":1,"cik":"0001677896","reported_name":"VARKI PAUL","relationship":{"director":false,"officer":true,"ten_percent_owner":false,"other":false,"officer_title":"Chief Legal Officer"}}],"security":"Common Stock","published_at":"2026-05-07T20:18:26.000Z","date":"2026-05-06","kind":"exercise","planned":true,"acquired":true,"shares":12563,"price":8.04,"value":101006.52,"ownership":{"direct":true},"footnotes":[{"field":"kind","element":"transactionCoding","label":"F1","text":"The transactions reported in this Form 4 were effected pursuant to a Rule 10b5-1 trading plan adopted by the Reporting Person on November 12, 2025."}],"balance_after":78697,"source":{"system":"sec-edgar","filing":"0001677896-26-000004","document":"form4-05072026_080504.xml","document_sequence":1,"table":"nonDerivative","row_type":"transaction","position":2,"url":"https://www.sec.gov/Archives/edgar/data/1534120/000167789626000004/form4-05072026_080504.xml","form_type":"4"}},{"id":788293,"issuer":{"id":4936,"kind":"organization","name":"Avalo Therapeutics, Inc.","symbol":"AVTX"},"owners":[{"id":38585,"kind":"person","name":"VARKI PAUL","position":1,"cik":"0001677896","reported_name":"VARKI PAUL","relationship":{"director":false,"officer":true,"ten_percent_owner":false,"other":false,"officer_title":"Chief Legal Officer"}}],"security":"Common Stock","published_at":"2026-05-07T20:18:26.000Z","date":"2026-05-06","kind":"exercise","planned":true,"acquired":true,"shares":62500,"price":13.43,"value":839375.0,"ownership":{"direct":true},"footnotes":[{"field":"kind","element":"transactionCoding","label":"F1","text":"The transactions reported in this Form 4 were effected pursuant to a Rule 10b5-1 trading plan adopted by the Reporting Person on November 12, 2025."}],"balance_after":66134,"source":{"system":"sec-edgar","filing":"0001677896-26-000004","document":"form4-05072026_080504.xml","document_sequence":1,"table":"nonDerivative","row_type":"transaction","position":1,"url":"https://www.sec.gov/Archives/edgar/data/1534120/000167789626000004/form4-05072026_080504.xml","form_type":"4"}},{"id":788548,"issuer":{"id":4936,"kind":"organization","name":"Avalo Therapeutics, Inc.","symbol":"AVTX"},"owners":[{"id":21663,"kind":"person","name":"Sullivan Christopher Ryan","position":1,"cik":"0001810417","reported_name":"Sullivan Christopher Ryan","relationship":{"director":false,"officer":true,"ten_percent_owner":false,"other":false,"officer_title":"Chief Financial Officer"}}],"security":"Stock Option (Right to Buy)","published_at":"2026-05-07T20:16:49.000Z","date":"2026-05-06","kind":"exercise","planned":true,"acquired":false,"shares":47000,"price":0,"value":0.0,"ownership":{"direct":true},"footnotes":[{"field":"kind","element":"transactionCoding","label":"F1","text":"The transactions reported in this Form 4 were effected pursuant to a Rule 10b5-1 trading plan adopted by the Reporting Person on November 12, 2025."},{"field":"derivative.exercise_date","element":"exerciseDate","label":"F7","text":"The stock option vests twenty-five percent (25%) on January 28, 2026 and the remainder will vest in equal monthly installments over the following three (3) years, subject to the Reporting Person's continued service on such vesting date."}],"balance_after":116000,"derivative":{"exercise_price":8.04,"expiration_date":"2035-01-28","underlying":"Common Stock","underlying_shares":47000},"source":{"system":"sec-edgar","filing":"0001810417-26-000010","document":"form4-05072026_080542.xml","document_sequence":1,"table":"derivative","row_type":"transaction","position":7,"url":"https://www.sec.gov/Archives/edgar/data/1810417/000181041726000010/form4-05072026_080542.xml","form_type":"4"}},{"id":788547,"issuer":{"id":4936,"kind":"organization","name":"Avalo Therapeutics, Inc.","symbol":"AVTX"},"owners":[{"id":21663,"kind":"person","name":"Sullivan Christopher Ryan","position":1,"cik":"0001810417","reported_name":"Sullivan Christopher Ryan","relationship":{"director":false,"officer":true,"ten_percent_owner":false,"other":false,"officer_title":"Chief Financial Officer"}}],"security":"Common Stock","published_at":"2026-05-07T20:16:49.000Z","date":"2026-05-06","kind":"sale","planned":true,"acquired":false,"shares":8900,"price":22.5745,"value":200913.05,"ownership":{"direct":true},"footnotes":[{"field":"kind","element":"transactionCoding","label":"F1","text":"The transactions reported in this Form 4 were effected pursuant to a Rule 10b5-1 trading plan adopted by the Reporting Person on November 12, 2025."},{"field":"price","element":"transactionPricePerShare","label":"F6","text":"The reported securities were sold in multiple transactions at prices ranging from $22.26 to $22.88. The Reporting Person undertakes to provide to the Issuer, any security holder of the Issuer or the staff of the Securities and Exchange Commission, upon request, full information regarding the number of shares sold at each separate price within such range."}],"balance_after":423,"source":{"system":"sec-edgar","filing":"0001810417-26-000010","document":"form4-05072026_080542.xml","document_sequence":1,"table":"nonDerivative","row_type":"transaction","position":6,"url":"https://www.sec.gov/Archives/edgar/data/1810417/000181041726000010/form4-05072026_080542.xml","form_type":"4"}},{"id":788546,"issuer":{"id":4936,"kind":"organization","name":"Avalo Therapeutics, Inc.","symbol":"AVTX"},"owners":[{"id":21663,"kind":"person","name":"Sullivan Christopher Ryan","position":1,"cik":"0001810417","reported_name":"Sullivan Christopher Ryan","relationship":{"director":false,"officer":true,"ten_percent_owner":false,"other":false,"officer_title":"Chief Financial Officer"}}],"security":"Common Stock","published_at":"2026-05-07T20:16:49.000Z","date":"2026-05-06","kind":"sale","planned":true,"acquired":false,"shares":9219,"price":21.3698,"value":197008.1862,"ownership":{"direct":true},"footnotes":[{"field":"kind","element":"transactionCoding","label":"F1","text":"The transactions reported in this Form 4 were effected pursuant to a Rule 10b5-1 trading plan adopted by the Reporting Person on November 12, 2025."},{"field":"price","element":"transactionPricePerShare","label":"F5","text":"The reported securities were sold in multiple transactions at prices ranging from $21.10 to $21.90. The Reporting Person undertakes to provide to the Issuer, any security holder of the Issuer or the staff of the Securities and Exchange Commission, upon request, full information regarding the number of shares sold at each separate price within such range."}],"balance_after":9323,"source":{"system":"sec-edgar","filing":"0001810417-26-000010","document":"form4-05072026_080542.xml","document_sequence":1,"table":"nonDerivative","row_type":"transaction","position":5,"url":"https://www.sec.gov/Archives/edgar/data/1810417/000181041726000010/form4-05072026_080542.xml","form_type":"4"}},{"id":788545,"issuer":{"id":4936,"kind":"organization","name":"Avalo Therapeutics, Inc.","symbol":"AVTX"},"owners":[{"id":21663,"kind":"person","name":"Sullivan Christopher Ryan","position":1,"cik":"0001810417","reported_name":"Sullivan Christopher Ryan","relationship":{"director":false,"officer":true,"ten_percent_owner":false,"other":false,"officer_title":"Chief Financial Officer"}}],"security":"Common Stock","published_at":"2026-05-07T20:16:49.000Z","date":"2026-05-06","kind":"sale","planned":true,"acquired":false,"shares":2700,"price":20.76,"value":56052.0,"ownership":{"direct":true},"footnotes":[{"field":"kind","element":"transactionCoding","label":"F1","text":"The transactions reported in this Form 4 were effected pursuant to a Rule 10b5-1 trading plan adopted by the Reporting Person on November 12, 2025."},{"field":"price","element":"transactionPricePerShare","label":"F4","text":"The reported securities were sold in multiple transactions at prices ranging from $20.04 to $20.81. The Reporting Person undertakes to provide to the Issuer, any security holder of the Issuer or the staff of the Securities and Exchange Commission, upon request, full information regarding the number of shares sold at each separate price within such range."}],"balance_after":18542,"source":{"system":"sec-edgar","filing":"0001810417-26-000010","document":"form4-05072026_080542.xml","document_sequence":1,"table":"nonDerivative","row_type":"transaction","position":4,"url":"https://www.sec.gov/Archives/edgar/data/1810417/000181041726000010/form4-05072026_080542.xml","form_type":"4"}},{"id":788544,"issuer":{"id":4936,"kind":"organization","name":"Avalo Therapeutics, Inc.","symbol":"AVTX"},"owners":[{"id":21663,"kind":"person","name":"Sullivan Christopher Ryan","position":1,"cik":"0001810417","reported_name":"Sullivan Christopher Ryan","relationship":{"director":false,"officer":true,"ten_percent_owner":false,"other":false,"officer_title":"Chief Financial Officer"}}],"security":"Common Stock","published_at":"2026-05-07T20:16:49.000Z","date":"2026-05-06","kind":"sale","planned":true,"acquired":false,"shares":12347,"price":19.2835,"value":238093.3745,"ownership":{"direct":true},"footnotes":[{"field":"kind","element":"transactionCoding","label":"F1","text":"The transactions reported in this Form 4 were effected pursuant to a Rule 10b5-1 trading plan adopted by the Reporting Person on November 12, 2025."},{"field":"price","element":"transactionPricePerShare","label":"F3","text":"The reported securities were sold in multiple transactions at prices ranging from $19.02 to $19.91. The Reporting Person undertakes to provide to the Issuer, any security holder of the Issuer or the staff of the Securities and Exchange Commission, upon request, full information regarding the number of shares sold at each separate price within such range."}],"balance_after":21242,"source":{"system":"sec-edgar","filing":"0001810417-26-000010","document":"form4-05072026_080542.xml","document_sequence":1,"table":"nonDerivative","row_type":"transaction","position":3,"url":"https://www.sec.gov/Archives/edgar/data/1810417/000181041726000010/form4-05072026_080542.xml","form_type":"4"}},{"id":788543,"issuer":{"id":4936,"kind":"organization","name":"Avalo Therapeutics, Inc.","symbol":"AVTX"},"owners":[{"id":21663,"kind":"person","name":"Sullivan Christopher Ryan","position":1,"cik":"0001810417","reported_name":"Sullivan Christopher Ryan","relationship":{"director":false,"officer":true,"ten_percent_owner":false,"other":false,"officer_title":"Chief Financial Officer"}}],"security":"Common Stock","published_at":"2026-05-07T20:16:49.000Z","date":"2026-05-06","kind":"sale","planned":true,"acquired":false,"shares":13834,"price":18.5525,"value":256655.285,"ownership":{"direct":true},"footnotes":[{"field":"kind","element":"transactionCoding","label":"F1","text":"The transactions reported in this Form 4 were effected pursuant to a Rule 10b5-1 trading plan adopted by the Reporting Person on November 12, 2025."},{"field":"price","element":"transactionPricePerShare","label":"F2","text":"The reported securities were sold in multiple transactions at prices ranging from $17.95 to $18.90. The Reporting Person undertakes to provide to the Issuer, any security holder of the Issuer or the staff of the Securities and Exchange Commission, upon request, full information regarding the number of shares sold at each separate price within such range."}],"balance_after":33589,"source":{"system":"sec-edgar","filing":"0001810417-26-000010","document":"form4-05072026_080542.xml","document_sequence":1,"table":"nonDerivative","row_type":"transaction","position":2,"url":"https://www.sec.gov/Archives/edgar/data/1810417/000181041726000010/form4-05072026_080542.xml","form_type":"4"}},{"id":788542,"issuer":{"id":4936,"kind":"organization","name":"Avalo Therapeutics, Inc.","symbol":"AVTX"},"owners":[{"id":21663,"kind":"person","name":"Sullivan Christopher Ryan","position":1,"cik":"0001810417","reported_name":"Sullivan Christopher Ryan","relationship":{"director":false,"officer":true,"ten_percent_owner":false,"other":false,"officer_title":"Chief Financial Officer"}}],"security":"Common Stock","published_at":"2026-05-07T20:16:49.000Z","date":"2026-05-06","kind":"exercise","planned":true,"acquired":true,"shares":47000,"price":8.04,"value":377880.0,"ownership":{"direct":true},"footnotes":[{"field":"kind","element":"transactionCoding","label":"F1","text":"The transactions reported in this Form 4 were effected pursuant to a Rule 10b5-1 trading plan adopted by the Reporting Person on November 12, 2025."}],"balance_after":47423,"source":{"system":"sec-edgar","filing":"0001810417-26-000010","document":"form4-05072026_080542.xml","document_sequence":1,"table":"nonDerivative","row_type":"transaction","position":1,"url":"https://www.sec.gov/Archives/edgar/data/1810417/000181041726000010/form4-05072026_080542.xml","form_type":"4"}},{"id":788292,"issuer":{"id":4936,"kind":"organization","name":"Avalo Therapeutics, Inc.","symbol":"AVTX"},"owners":[{"id":17865,"kind":"person","name":"Doyle Mittie","position":1,"cik":"0001918845","reported_name":"Doyle Mittie","relationship":{"director":false,"officer":true,"ten_percent_owner":false,"other":false,"officer_title":"Chief Medical Officer"}}],"security":"Stock Option (Right to Buy)","published_at":"2026-05-07T20:16:14.000Z","date":"2026-05-06","kind":"exercise","planned":true,"acquired":false,"shares":28650,"price":0,"value":0.0,"ownership":{"direct":true},"footnotes":[{"field":"kind","element":"transactionCoding","label":"F1","text":"The transactions reported in this Form 4 were effected pursuant to a Rule 10b5-1 trading plan adopted by the Reporting Person on November 13, 2025."},{"field":"derivative.exercise_date","element":"exerciseDate","label":"F7","text":"The stock option vests twenty-five percent (25%) on January 28, 2026 and the remainder will vest in equal monthly installments over the following three (3) years, subject to the Reporting Person's continued service on each such vesting date."}],"balance_after":119000,"derivative":{"exercise_price":8.04,"expiration_date":"2035-01-28","underlying":"Common Stock","underlying_shares":28650},"source":{"system":"sec-edgar","filing":"0001918845-26-000010","document":"form4-05072026_080500.xml","document_sequence":1,"table":"derivative","row_type":"transaction","position":14,"url":"https://www.sec.gov/Archives/edgar/data/1534120/000191884526000010/form4-05072026_080500.xml","form_type":"4"}},{"id":788291,"issuer":{"id":4936,"kind":"organization","name":"Avalo Therapeutics, Inc.","symbol":"AVTX"},"owners":[{"id":17865,"kind":"person","name":"Doyle Mittie","position":1,"cik":"0001918845","reported_name":"Doyle Mittie","relationship":{"director":false,"officer":true,"ten_percent_owner":false,"other":false,"officer_title":"Chief Medical Officer"}}],"security":"Stock Option (Right to Buy)","published_at":"2026-05-07T20:16:14.000Z","date":"2026-05-06","kind":"exercise","planned":true,"acquired":false,"shares":77905,"price":0,"value":0.0,"ownership":{"direct":true},"footnotes":[{"field":"kind","element":"transactionCoding","label":"F1","text":"The transactions reported in this Form 4 were effected pursuant to a Rule 10b5-1 trading plan adopted by the Reporting Person on November 13, 2025."},{"field":"derivative.exercise_date","element":"exerciseDate","label":"F6","text":"The stock option vests twenty-five percent (25%) on July 15, 2025 and the remainder will vest in equal monthly installments over the following three (3) years, subject to the Reporting Person's continued service on each such vesting date."}],"balance_after":131625,"derivative":{"exercise_price":12.65,"expiration_date":"2034-07-15","underlying":"Common Stock","underlying_shares":77905},"source":{"system":"sec-edgar","filing":"0001918845-26-000010","document":"form4-05072026_080500.xml","document_sequence":1,"table":"derivative","row_type":"transaction","position":13,"url":"https://www.sec.gov/Archives/edgar/data/1534120/000191884526000010/form4-05072026_080500.xml","form_type":"4"}},{"id":788290,"issuer":{"id":4936,"kind":"organization","name":"Avalo Therapeutics, Inc.","symbol":"AVTX"},"owners":[{"id":17865,"kind":"person","name":"Doyle Mittie","position":1,"cik":"0001918845","reported_name":"Doyle Mittie","relationship":{"director":false,"officer":true,"ten_percent_owner":false,"other":false,"officer_title":"Chief Medical Officer"}}],"security":"Stock Option (Right to Buy)","published_at":"2026-05-07T20:16:14.000Z","date":"2026-05-05","kind":"exercise","planned":true,"acquired":false,"shares":679,"price":0,"value":0.0,"ownership":{"direct":true},"footnotes":[{"field":"kind","element":"transactionCoding","label":"F1","text":"The transactions reported in this Form 4 were effected pursuant to a Rule 10b5-1 trading plan adopted by the Reporting Person on November 13, 2025."},{"field":"derivative.exercise_date","element":"exerciseDate","label":"F7","text":"The stock option vests twenty-five percent (25%) on January 28, 2026 and the remainder will vest in equal monthly installments over the following three (3) years, subject to the Reporting Person's continued service on each such vesting date."}],"balance_after":147650,"derivative":{"exercise_price":8.04,"expiration_date":"2035-01-28","underlying":"Common Stock","underlying_shares":679},"source":{"system":"sec-edgar","filing":"0001918845-26-000010","document":"form4-05072026_080500.xml","document_sequence":1,"table":"derivative","row_type":"transaction","position":12,"url":"https://www.sec.gov/Archives/edgar/data/1534120/000191884526000010/form4-05072026_080500.xml","form_type":"4"}},{"id":788289,"issuer":{"id":4936,"kind":"organization","name":"Avalo Therapeutics, Inc.","symbol":"AVTX"},"owners":[{"id":17865,"kind":"person","name":"Doyle Mittie","position":1,"cik":"0001918845","reported_name":"Doyle Mittie","relationship":{"director":false,"officer":true,"ten_percent_owner":false,"other":false,"officer_title":"Chief Medical Officer"}}],"security":"Stock Option (Right to Buy)","published_at":"2026-05-07T20:16:14.000Z","date":"2026-05-05","kind":"exercise","planned":true,"acquired":false,"shares":1000,"price":0,"value":0.0,"ownership":{"direct":true},"footnotes":[{"field":"kind","element":"transactionCoding","label":"F1","text":"The transactions reported in this Form 4 were effected pursuant to a Rule 10b5-1 trading plan adopted by the Reporting Person on November 13, 2025."},{"field":"derivative.exercise_date","element":"exerciseDate","label":"F6","text":"The stock option vests twenty-five percent (25%) on July 15, 2025 and the remainder will vest in equal monthly installments over the following three (3) years, subject to the Reporting Person's continued service on each such vesting date."}],"balance_after":209530,"derivative":{"exercise_price":12.65,"expiration_date":"2034-07-15","underlying":"Common Stock","underlying_shares":1000},"source":{"system":"sec-edgar","filing":"0001918845-26-000010","document":"form4-05072026_080500.xml","document_sequence":1,"table":"derivative","row_type":"transaction","position":11,"url":"https://www.sec.gov/Archives/edgar/data/1534120/000191884526000010/form4-05072026_080500.xml","form_type":"4"}},{"id":788288,"issuer":{"id":4936,"kind":"organization","name":"Avalo Therapeutics, Inc.","symbol":"AVTX"},"owners":[{"id":17865,"kind":"person","name":"Doyle Mittie","position":1,"cik":"0001918845","reported_name":"Doyle Mittie","relationship":{"director":false,"officer":true,"ten_percent_owner":false,"other":false,"officer_title":"Chief Medical Officer"}}],"security":"Common Stock","published_at":"2026-05-07T20:16:14.000Z","date":"2026-05-06","kind":"sale","planned":true,"acquired":false,"shares":10058,"price":22.88,"value":230127.04,"ownership":{"direct":true},"footnotes":[{"field":"kind","element":"transactionCoding","label":"F1","text":"The transactions reported in this Form 4 were effected pursuant to a Rule 10b5-1 trading plan adopted by the Reporting Person on November 13, 2025."}],"balance_after":3622,"source":{"system":"sec-edgar","filing":"0001918845-26-000010","document":"form4-05072026_080500.xml","document_sequence":1,"table":"nonDerivative","row_type":"transaction","position":10,"url":"https://www.sec.gov/Archives/edgar/data/1534120/000191884526000010/form4-05072026_080500.xml","form_type":"4"}},{"id":788287,"issuer":{"id":4936,"kind":"organization","name":"Avalo Therapeutics, Inc.","symbol":"AVTX"},"owners":[{"id":17865,"kind":"person","name":"Doyle Mittie","position":1,"cik":"0001918845","reported_name":"Doyle Mittie","relationship":{"director":false,"officer":true,"ten_percent_owner":false,"other":false,"officer_title":"Chief Medical Officer"}}],"security":"Common Stock","published_at":"2026-05-07T20:16:14.000Z","date":"2026-05-06","kind":"sale","planned":true,"acquired":false,"shares":19015,"price":22.406,"value":426050.09,"ownership":{"direct":true},"footnotes":[{"field":"kind","element":"transactionCoding","label":"F1","text":"The transactions reported in this Form 4 were effected pursuant to a Rule 10b5-1 trading plan adopted by the Reporting Person on November 13, 2025."},{"field":"price","element":"transactionPricePerShare","label":"F5","text":"The reported securities were sold in multiple transactions at prices ranging from $21.83 to $22.80. The reporting person undertakes to provide to the Issuer, any security holder of the Issuer or the staff of the Securities and Exchange Commission, upon request, full information regarding the number of shares sold at each separate price within such range."}],"balance_after":13680,"source":{"system":"sec-edgar","filing":"0001918845-26-000010","document":"form4-05072026_080500.xml","document_sequence":1,"table":"nonDerivative","row_type":"transaction","position":9,"url":"https://www.sec.gov/Archives/edgar/data/1534120/000191884526000010/form4-05072026_080500.xml","form_type":"4"}},{"id":788286,"issuer":{"id":4936,"kind":"organization","name":"Avalo Therapeutics, Inc.","symbol":"AVTX"},"owners":[{"id":17865,"kind":"person","name":"Doyle Mittie","position":1,"cik":"0001918845","reported_name":"Doyle Mittie","relationship":{"director":false,"officer":true,"ten_percent_owner":false,"other":false,"officer_title":"Chief Medical Officer"}}],"security":"Common Stock","published_at":"2026-05-07T20:16:14.000Z","date":"2026-05-06","kind":"sale","planned":true,"acquired":false,"shares":44944,"price":21.1968,"value":952668.9792,"ownership":{"direct":true},"footnotes":[{"field":"kind","element":"transactionCoding","label":"F1","text":"The transactions reported in this Form 4 were effected pursuant to a Rule 10b5-1 trading plan adopted by the Reporting Person on November 13, 2025."},{"field":"price","element":"transactionPricePerShare","label":"F4","text":"The reported securities were sold in multiple transactions at prices ranging from $20.75 to $21.69. The reporting person undertakes to provide to the Issuer, any security holder of the Issuer or the staff of the Securities and Exchange Commission, upon request, full information regarding the number of shares sold at each separate price within such range."}],"balance_after":32695,"source":{"system":"sec-edgar","filing":"0001918845-26-000010","document":"form4-05072026_080500.xml","document_sequence":1,"table":"nonDerivative","row_type":"transaction","position":8,"url":"https://www.sec.gov/Archives/edgar/data/1534120/000191884526000010/form4-05072026_080500.xml","form_type":"4"}},{"id":788285,"issuer":{"id":4936,"kind":"organization","name":"Avalo Therapeutics, Inc.","symbol":"AVTX"},"owners":[{"id":17865,"kind":"person","name":"Doyle Mittie","position":1,"cik":"0001918845","reported_name":"Doyle Mittie","relationship":{"director":false,"officer":true,"ten_percent_owner":false,"other":false,"officer_title":"Chief Medical Officer"}}],"security":"Common Stock","published_at":"2026-05-07T20:16:14.000Z","date":"2026-05-06","kind":"sale","planned":true,"acquired":false,"shares":5000,"price":19.6502,"value":98251.0,"ownership":{"direct":true},"footnotes":[{"field":"kind","element":"transactionCoding","label":"F1","text":"The transactions reported in this Form 4 were effected pursuant to a Rule 10b5-1 trading plan adopted by the Reporting Person on November 13, 2025."},{"field":"price","element":"transactionPricePerShare","label":"F3","text":"The reported securities were sold in multiple transactions at prices ranging from $19.08 to $19.99. The reporting person undertakes to provide to the Issuer, any security holder of the Issuer or the staff of the Securities and Exchange Commission, upon request, full information regarding the number of shares sold at each separate price within such range."}],"balance_after":77639,"source":{"system":"sec-edgar","filing":"0001918845-26-000010","document":"form4-05072026_080500.xml","document_sequence":1,"table":"nonDerivative","row_type":"transaction","position":7,"url":"https://www.sec.gov/Archives/edgar/data/1534120/000191884526000010/form4-05072026_080500.xml","form_type":"4"}},{"id":788284,"issuer":{"id":4936,"kind":"organization","name":"Avalo Therapeutics, Inc.","symbol":"AVTX"},"owners":[{"id":17865,"kind":"person","name":"Doyle Mittie","position":1,"cik":"0001918845","reported_name":"Doyle Mittie","relationship":{"director":false,"officer":true,"ten_percent_owner":false,"other":false,"officer_title":"Chief Medical Officer"}}],"security":"Common Stock","published_at":"2026-05-07T20:16:14.000Z","date":"2026-05-06","kind":"sale","planned":true,"acquired":false,"shares":27538,"price":18.0262,"value":496405.4956,"ownership":{"direct":true},"footnotes":[{"field":"kind","element":"transactionCoding","label":"F1","text":"The transactions reported in this Form 4 were effected pursuant to a Rule 10b5-1 trading plan adopted by the Reporting Person on November 13, 2025."},{"field":"price","element":"transactionPricePerShare","label":"F2","text":"The reported securities were sold in multiple transactions at prices ranging from $18.00 to $18.97. The Reporting Person undertakes to provide to the Issuer, any security holder of the Issuer or the staff of the Securities and Exchange Commission, upon request, full information regarding the number of shares sold at each separate price within such range."}],"balance_after":82639,"source":{"system":"sec-edgar","filing":"0001918845-26-000010","document":"form4-05072026_080500.xml","document_sequence":1,"table":"nonDerivative","row_type":"transaction","position":6,"url":"https://www.sec.gov/Archives/edgar/data/1534120/000191884526000010/form4-05072026_080500.xml","form_type":"4"}},{"id":788283,"issuer":{"id":4936,"kind":"organization","name":"Avalo Therapeutics, Inc.","symbol":"AVTX"},"owners":[{"id":17865,"kind":"person","name":"Doyle Mittie","position":1,"cik":"0001918845","reported_name":"Doyle Mittie","relationship":{"director":false,"officer":true,"ten_percent_owner":false,"other":false,"officer_title":"Chief Medical Officer"}}],"security":"Common Stock","published_at":"2026-05-07T20:16:14.000Z","date":"2026-05-06","kind":"exercise","planned":true,"acquired":true,"shares":28650,"price":8.04,"value":230346.0,"ownership":{"direct":true},"footnotes":[{"field":"kind","element":"transactionCoding","label":"F1","text":"The transactions reported in this Form 4 were effected pursuant to a Rule 10b5-1 trading plan adopted by the Reporting Person on November 13, 2025."}],"balance_after":110177,"source":{"system":"sec-edgar","filing":"0001918845-26-000010","document":"form4-05072026_080500.xml","document_sequence":1,"table":"nonDerivative","row_type":"transaction","position":5,"url":"https://www.sec.gov/Archives/edgar/data/1534120/000191884526000010/form4-05072026_080500.xml","form_type":"4"}},{"id":788282,"issuer":{"id":4936,"kind":"organization","name":"Avalo Therapeutics, Inc.","symbol":"AVTX"},"owners":[{"id":17865,"kind":"person","name":"Doyle Mittie","position":1,"cik":"0001918845","reported_name":"Doyle Mittie","relationship":{"director":false,"officer":true,"ten_percent_owner":false,"other":false,"officer_title":"Chief Medical Officer"}}],"security":"Common Stock","published_at":"2026-05-07T20:16:14.000Z","date":"2026-05-06","kind":"exercise","planned":true,"acquired":true,"shares":77905,"price":12.65,"value":985498.25,"ownership":{"direct":true},"footnotes":[{"field":"kind","element":"transactionCoding","label":"F1","text":"The transactions reported in this Form 4 were effected pursuant to a Rule 10b5-1 trading plan adopted by the Reporting Person on November 13, 2025."}],"balance_after":81527,"source":{"system":"sec-edgar","filing":"0001918845-26-000010","document":"form4-05072026_080500.xml","document_sequence":1,"table":"nonDerivative","row_type":"transaction","position":4,"url":"https://www.sec.gov/Archives/edgar/data/1534120/000191884526000010/form4-05072026_080500.xml","form_type":"4"}},{"id":788281,"issuer":{"id":4936,"kind":"organization","name":"Avalo Therapeutics, Inc.","symbol":"AVTX"},"owners":[{"id":17865,"kind":"person","name":"Doyle Mittie","position":1,"cik":"0001918845","reported_name":"Doyle Mittie","relationship":{"director":false,"officer":true,"ten_percent_owner":false,"other":false,"officer_title":"Chief Medical Officer"}}],"security":"Common Stock","published_at":"2026-05-07T20:16:14.000Z","date":"2026-05-05","kind":"sale","planned":true,"acquired":false,"shares":1679,"price":16,"value":26864.0,"ownership":{"direct":true},"footnotes":[{"field":"kind","element":"transactionCoding","label":"F1","text":"The transactions reported in this Form 4 were effected pursuant to a Rule 10b5-1 trading plan adopted by the Reporting Person on November 13, 2025."}],"balance_after":3622,"source":{"system":"sec-edgar","filing":"0001918845-26-000010","document":"form4-05072026_080500.xml","document_sequence":1,"table":"nonDerivative","row_type":"transaction","position":3,"url":"https://www.sec.gov/Archives/edgar/data/1534120/000191884526000010/form4-05072026_080500.xml","form_type":"4"}},{"id":788280,"issuer":{"id":4936,"kind":"organization","name":"Avalo Therapeutics, Inc.","symbol":"AVTX"},"owners":[{"id":17865,"kind":"person","name":"Doyle Mittie","position":1,"cik":"0001918845","reported_name":"Doyle Mittie","relationship":{"director":false,"officer":true,"ten_percent_owner":false,"other":false,"officer_title":"Chief Medical Officer"}}],"security":"Common Stock","published_at":"2026-05-07T20:16:14.000Z","date":"2026-05-05","kind":"exercise","planned":true,"acquired":true,"shares":679,"price":8.04,"value":5459.16,"ownership":{"direct":true},"footnotes":[{"field":"kind","element":"transactionCoding","label":"F1","text":"The transactions reported in this Form 4 were effected pursuant to a Rule 10b5-1 trading plan adopted by the Reporting Person on November 13, 2025."}],"balance_after":5301,"source":{"system":"sec-edgar","filing":"0001918845-26-000010","document":"form4-05072026_080500.xml","document_sequence":1,"table":"nonDerivative","row_type":"transaction","position":2,"url":"https://www.sec.gov/Archives/edgar/data/1534120/000191884526000010/form4-05072026_080500.xml","form_type":"4"}},{"id":788279,"issuer":{"id":4936,"kind":"organization","name":"Avalo Therapeutics, Inc.","symbol":"AVTX"},"owners":[{"id":17865,"kind":"person","name":"Doyle Mittie","position":1,"cik":"0001918845","reported_name":"Doyle Mittie","relationship":{"director":false,"officer":true,"ten_percent_owner":false,"other":false,"officer_title":"Chief Medical Officer"}}],"security":"Common Stock","published_at":"2026-05-07T20:16:14.000Z","date":"2026-05-05","kind":"exercise","planned":true,"acquired":true,"shares":1000,"price":12.65,"value":12650.0,"ownership":{"direct":true},"footnotes":[{"field":"kind","element":"transactionCoding","label":"F1","text":"The transactions reported in this Form 4 were effected pursuant to a Rule 10b5-1 trading plan adopted by the Reporting Person on November 13, 2025."}],"balance_after":4622,"source":{"system":"sec-edgar","filing":"0001918845-26-000010","document":"form4-05072026_080500.xml","document_sequence":1,"table":"nonDerivative","row_type":"transaction","position":1,"url":"https://www.sec.gov/Archives/edgar/data/1534120/000191884526000010/form4-05072026_080500.xml","form_type":"4"}},{"id":788278,"issuer":{"id":4936,"kind":"organization","name":"Avalo Therapeutics, Inc.","symbol":"AVTX"},"owners":[{"id":2213,"kind":"person","name":"Chan Mitchell","position":1,"cik":"0001789335","reported_name":"Chan Mitchell","relationship":{"director":true,"officer":false,"ten_percent_owner":false,"other":false}}],"security":"Common Stock","published_at":"2026-05-07T20:15:10.000Z","date":"2026-05-06","kind":"sale","planned":true,"acquired":false,"shares":3167,"price":22.88,"value":72460.96,"ownership":{"direct":true},"footnotes":[{"field":"kind","element":"transactionCoding","label":"F1","text":"The transactions reported in this Form 4 were effected pursuant to a Rule 10b5-1 trading plan adopted by the Reporting Person on November 19, 2025."}],"balance_after":3166,"source":{"system":"sec-edgar","filing":"0001789335-26-000006","document":"form4-05072026_080503.xml","document_sequence":1,"table":"nonDerivative","row_type":"transaction","position":1,"url":"https://www.sec.gov/Archives/edgar/data/1534120/000178933526000006/form4-05072026_080503.xml","form_type":"4"}},{"id":795784,"issuer":{"id":4936,"kind":"organization","name":"Avalo Therapeutics, Inc.","symbol":"AVTX"},"owners":[{"id":21663,"kind":"person","name":"Sullivan Christopher Ryan","position":1,"cik":"0001810417","reported_name":"Sullivan Christopher Ryan","relationship":{"director":false,"officer":true,"ten_percent_owner":false,"other":false,"officer_title":"Chief Financial Officer"}}],"security":"Common Stock","published_at":"2026-05-01T20:37:50.000Z","date":"2026-04-30","kind":"sale","planned":true,"acquired":false,"shares":8457,"price":13.2261,"value":111853.1277,"ownership":{"direct":true},"footnotes":[{"field":"kind","element":"transactionCoding","label":"F1","text":"The transactions reported in this Form 4 were effected pursuant to a Rule 10b5-1 trading plan adopted by the Reporting Person on November 12, 2025."},{"field":"price","element":"transactionPricePerShare","label":"F3","text":"The reported securities were sold in multiple transactions at prices ranging from $12.61 to $13.54. The Reporting Person undertakes to provide to the Issuer, any security holder of the Issuer or the staff of the Securities and Exchange Commission, upon request, full information regarding the number of shares sold at each separate price within such range."}],"balance_after":423,"source":{"system":"sec-edgar","filing":"0001810417-26-000008","document":"form4-05012026_080546.xml","document_sequence":1,"table":"nonDerivative","row_type":"transaction","position":2,"url":"https://www.sec.gov/Archives/edgar/data/1810417/000181041726000008/form4-05012026_080546.xml","form_type":"4"}},{"id":795783,"issuer":{"id":4936,"kind":"organization","name":"Avalo Therapeutics, Inc.","symbol":"AVTX"},"owners":[{"id":21663,"kind":"person","name":"Sullivan Christopher Ryan","position":1,"cik":"0001810417","reported_name":"Sullivan Christopher Ryan","relationship":{"director":false,"officer":true,"ten_percent_owner":false,"other":false,"officer_title":"Chief Financial Officer"}}],"security":"Common Stock","published_at":"2026-05-01T20:37:50.000Z","date":"2026-04-29","kind":"sale","planned":true,"acquired":false,"shares":8458,"price":13.0925,"value":110736.365,"ownership":{"direct":true},"footnotes":[{"field":"kind","element":"transactionCoding","label":"F1","text":"The transactions reported in this Form 4 were effected pursuant to a Rule 10b5-1 trading plan adopted by the Reporting Person on November 12, 2025."},{"field":"price","element":"transactionPricePerShare","label":"F2","text":"The reported securities were sold in multiple transactions at prices ranging from $12.74 to $13.50. The Reporting Person undertakes to provide to the Issuer, any security holder of the Issuer or the staff of the Securities and Exchange Commission, upon request, full information regarding the number of shares sold at each separate price within such range."}],"balance_after":8880,"source":{"system":"sec-edgar","filing":"0001810417-26-000008","document":"form4-05012026_080546.xml","document_sequence":1,"table":"nonDerivative","row_type":"transaction","position":1,"url":"https://www.sec.gov/Archives/edgar/data/1810417/000181041726000008/form4-05012026_080546.xml","form_type":"4"}}],"next_cursor":"2026-05-01T20:37:50.000000Z,795783"}